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Summary 
 
Alzheimer’s disease (AD) is an incurable and devastating neurodegenerative disorder characterized by 
progressive decline in memory and other cognitive functions ultimately leading to a dementia 
syndrome when the patient is incapable of independent living. Current treatments provide only 
temporary symptomatic stabilisation. Improved treatment methods that are now under investigation 
may be most efficacious in preclinical or early disease stages (Golde, Schneider, & Koo, 2011; 
Sperling, Jack, & Aisen, 2011), referred to as mild cognitive impairment (MCI). However, some MCI 
patients develop dementia other than AD, whereas others remain stable or even recover (Roberts et al., 
2014). Accordingly, the establishment of markers that accurately identify future converters to AD 
represents a major contemporary goal in AD research worldwide. 
Structural magnetic resonance imaging (MRI) represents a key imaging marker for the early detection 
of AD. It allows the quantification of brain atrophy due to early involvement of neurofibrillary tangle 
formation followed by neuronal loss. Although hippocampal atrophy represents a well-established 
imaging marker for AD, gray matter volume alterations of a single structures may not specifically be 
associated with AD pathology (van de Pol et al., 2006), and thus might not be sufficient to characterize 
the spreading pattern of AD pathology across the brain. Taking into account more regional 
information about volume and shape of further subcortical structures thus might enhance the early 
detection of AD. 
Similarly, impaired episodic memory performance has demonstrated predictive value for conversion 
from MCI to AD (for an overview see Gainotti, Quaranta, Vita, & Marra, 2014). Nevertheless, the 
discrimination between impaired cognitive abilities due to low educational background, state-based 
cognitive fluctuations and AD-related cognitive impairment is challenging (Kliegel & Sliwinski, 
2004). Previous studies have demonstrated that considering intraindividual variability (IIV) across 
accuracy scores (accuracy-based IIV) obtained from tests representing different cognitive domains 
(across-domain IIV) might increase the prediction of AD (Holtzer, Verghese, Wang, Hall, & Lipton, 
2008). Marked IIV is thought to reflect impairment of cognitive control functions, supported by 
specific regions in prefrontal (Levy & Wagner, 2011; Weissman, Roberts, Visscher, & Woldorff, 
2006) and parietal (Wilk, Ezekiel, & Morton, 2012) cortices. However, accuracy-based IIV across 
tests of cognitive control functions (within-domain IIV) has not been examined in AD. Thus, the aim 
of the present work was to investigate the value of accuracy-based IIV and shape alterations in 
subcortical structures as cognitive and morphometric markers for the early detection of AD. 
The first study was performed to gain information about two different accuracy-based IIV scores in 
AD. Specifically, across-domain IIV and within-domain IIV were compared between healthy control 
subjects (HCS), MCI and AD patients. Both IIV scores were increased in AD when compared with 
HCS. However, only across-domain IIV was higher in AD than in MCI, and only within-domain IIV  
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was higher in MCI than in HCS. Thus, results indicate that within-domain IIV in particular might 
represent a marker for the detection of prodromal AD at the MCI stage, whereas across-domain IIV 
may detect beginning AD at the MCI stage.  
Accordingly, the second study aimed to explore whether within-domain IIV might act as an early 
marker for AD. For this aim, IIV was investigated in MCI with stable cognitive abilities (MCI-S), 
MCI with future conversion to AD at baseline (MCI-CB) and HCS. A further aim involved 
investigating the relationship between within-domain IIV and gray matter volumes of IIV-relevant 
regions such as dorsolateral and ventrolateral prefrontal as well as posterior parietal cortices (Levy & 
Wagner, 2011; Weissman et al., 2006; Wilk et al., 2012), obtained by MRI. In contrast to a previous 
study (Lövdén et al., 2013), within-domain IIV was not associated with regional gray matter volumes 
in either of the groups. Considering results from studies investigating neuronal correlates of IIV across 
reaction time tasks (latency-based IIV) (e.g Bunce et al., 2013) and previously reported relationships 
between latency- and accuracy-based IIV (Hilborn, Strauss, Hultsch, & Hunter, 2009; Hultsch, 
MacDonald, & Dixon, 2002), within-domain IIV might be associated with white matter rather than 
with gray matter alterations. More importantly, however, within-domain IIV was not increased in 
MCI-S nor in MCI-CB or in pooled MCI when compared with HCS. Although the low samples size in 
this study together with the low characterization of accuracy-based IIV in general (Hultsch, 
MacDonald, Hunter, Levy-Bencheton, & Strauss, 2000) might have triggered this finding, within-
domain IIV was found to have questionable value as an early marker of AD.  
The third study investigated whether subcortical shape alterations assessed by MRI might support the 
characterization of future converters to AD. Based on early AD pathology (Braak & Braak, 1990, 
1991a) and the pronounced connection of the thalamus and striatum to other AD-relevant structures 
such as the hippocampus (Zarei et al., 2010), shape alterations in the thalamus and striatum were 
investigated in MCI-S, MCI-CB and in MCI-CB at time of conversion (MCI-CC). At the same time, 
established morphometric markers such as cortical thickness and hippocampal total and subfield 
volumes were investigated. Results demonstrated the simultaneous presence of thalamic and striatal 
shape alterations, AD-typical mediotemporal cortical thinning and hippocampal atrophy in MCI-CB 
and MCI-CC but not in MCI-S. These results highlight the value of subcortical shape alterations as an 
early marker for AD, and emphasize the importance of considering regional morphological 
information from subcortical structures.  
In conclusion, findings from the present work support the value of thalamic and striatal shape 
alterations to further improve the identification of subjects at high risk for AD whereas within-domain 
IIV has questionable value as an early marker for AD and needs further exploration. Generally 
speaking, the present findings further emphasize the key role of morphometric markers for the 
characterization of early AD stages and indicate a potentially superior role of morphometric over 
cognitive markers. The value of cognitive markers, particularly when assessed on one single occasion, 
might be restricted due to limitations inherent to the cognitive tests themselves. 
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Zusammenfassung 
 
Die Alzheimer-Krankheit (AK) ist eine neurodegenerative Krankheit, welche aufgrund zunehmender 
kognitiver Beeinträchtigungen zu Demenz und schliesslich zum Verlust der persönlichen 
Unabhängigkeit führt. Die Wirkung aktuell zugelassener Behandlungsmethoden geht dabei nicht über 
eine vorübergehende symptomatische Stabilisierung hinaus. Neue Behandlungsmethoden werden 
aktuell untersucht, wobei Studienresultate darauf hinweisen, dass deren Wirksamkeit in präklinischen 
oder frühen Krankheitsphasen am höchsten ist (Golde et al., 2011; Sperling, Jack, et al., 2011). Die 
frühe Krankheitsphase zeichnet sich durch eine leichte kognitive Beeinträchtigung (LKB) aus, wobei 
nicht alle Patienten mit LKB eine AK entwickeln. Vielmehr gibt es Patienten die andere 
Demenzformen entwickeln sowie Patienten, deren kognitive Beeinträchtigungen über lange Zeit stabil 
bleiben oder sich wieder normalisieren (Roberts et al., 2014). Aufgrund dieser Heterogenität stellt die 
Entwicklung von Markern zur Identifizierung von künftigen AK-Patienten eines der Hauptziele der 
AK-Forschung weltweit dar. 
Die Verwendung struktureller Magnetresonanztomographie (MRT) hat wesentlich zur Identifizierung 
wichtiger Marker beigetragen. Mittels MRT kann die Atrophie quantifiziert werden, welche sich 
aufgrund der Bildung von Neurofibrillen und anschliessendem Neuronen Verlust in den Gehirnen von 
AK-Patienten manifestiert. Obwohl sich insbesondere die Atrophie im Hippocampus als 
Früherkennungsmarker etabliert hat, muss diese nicht zwangsläufig mit AK in Zusammenhang stehen 
(van de Pol et al., 2006). Es ist deshalb fraglich, ob die Berücksichtigung von Veränderungen in einer 
einzelnen Hirnstruktur ausreicht, um die sich im Gehirn ausbreitende AK-Pathologie angemessen zu 
charakterisieren. Der Miteinbezug weiterer struktureller Veränderungen, insbesondere regionaler 
Veränderungen subkortikaler Strukturen, könnte entsprechend zur Verbesserung der Früherkennung 
beitragen.  
Neben den MRT-Markern haben auch beeinträchtigte Leistungen im episodischen Gedächtnis einen 
hohen Vorhersagewert für die Entwicklung einer AK bewiesen (Überblick in Gainotti et al., 2014). Im 
klinischen Alltag stellt die Unterscheidung kognitiver Beeinträchtigungen aufgrund eines niedrigen 
Bildungshintergrundes, situationsbedingter kognitiver Fluktuationen oder LKB aufgrund von AK 
allerdings eine Herausforderung dar (Kliegel & Sliwinski, 2004). Bisherige Studien haben gezeigt, 
dass die Früherkennung von AK verbessert werden kann, wenn die kognitive intraindividuelle 
Variabilität (IIV) berücksichtigt wird (Holtzer et al., 2008). Dabei wurde IIV über Trefferquoten in 
Aufgaben berechnet, welche Leistungen verschiedener kognitiver Domänen erfassten 
(domänenübergreifende IIV). Erhöhte IIV wurde wiederholt mit beeinträchtigten kognitiven 
Kontrollfunktionen (West, Murphy, Armilio, Craik, & Stuss, 2002) sowie präfrontalen (Levy & 
Wagner, 2011; Weissman et al., 2006) und parietalen (Wilk et al., 2012) Hirnregionen in Verbindung 
gebracht. Dennoch gibt es kaum Studien, die in LKB- oder AK-Patienten IIV über Trefferquoten von 
Aufgaben untersucht haben, welche verstärkt kognitive Kontrollfunktionen beanspruchen 
(domänenspezifische IIV). Das Ziel der vorliegenden Arbeit war es deshalb zu untersuchen, ob IIV 
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über Trefferquoten sowie Formveränderungen in subkortikalen Strukturen als kognitive respektive 
morphometrische Marker zur Früherkennung von AK beitragen können.  
Mit der ersten Studie sollten dabei allgemeine Informationen zu den zwei unterschiedlichen IIV-
Werten (domänenübergreifende und domänenspezifische IIV) in AK gewonnen werden. Zu diesem 
Zweck wurden die beiden IIV-Werte von Patienten mit LKB und AK mit IIV-Werten von gesunden 
Kontrollpersonen (GKP) verglichen. Dabei stellten sich beide IIV-Werte in AK-Patienten im 
Vergleich zu GKP als erhöht heraus. Zudem war die domänenübergreifende IIV in AK-Patienten 
höher als in LKB, während die domänenspezifische IIV bei LKB höher war als in GKP. Damit liefern 
die Resultate der ersten Studie Hinweise darauf, dass insbesondere die domänenspezifische IIV zur 
Früherkennung von AK in LKB beitragen könnte. 
Diese Annahme wurde mit der zweiten Studie näher untersucht. Zu diesem Zweck wurde die 
domänenspezifische IIV in LKB mit stabilen kognitiven Fähigkeiten (LKB-S), in LKB mit späterer 
Entwicklung von AK unter Verwendung des Ausgangswertes (LKB-AKA) und in GKP untersucht. 
Zudem sollte der Zusammenhang zwischen IIV und dem Volumen der grauen Hirnsubstanz in IIV-
relevanten Regionen untersucht werden. Diese wurden mittels strukturellem MRT gemessen und 
umfassten dorsolaterale und ventrolaterale präfrontale sowie posteriore parietale Rindengebiete (Levy 
& Wagner, 2011; Weissman et al., 2006; Wilk et al., 2012). Im Gegensatz zu Resultaten einer früheren 
Studie (Lövdén et al., 2013) wurde dieser Zusammenhang in der vorliegenden Studie in keiner der 
untersuchten Gruppen gefunden. Diverse Studien haben einen Zusammenhang zwischen IIV über 
Reaktionszeiten und Veränderungen in der weissen Hirnsubstanz gefunden (z.B. Bunce et al., 2013). 
Weitere Studien haben zudem gezeigt, dass IIV über Reaktionszeiten und IIV über Trefferquoten 
korreliert sind (Hilborn et al., 2009; Hultsch et al., 2002). Diese Resultate weisen darauf hin, dass 
domänenspezifische IIV allenfalls eher mit Veränderungen in der weissen statt mit Veränderungen in 
der grauen Hirnsubstanz in Zusammenhang stehen könnte. Im Gegensatz zu den Resultaten der ersten 
Studie hat sich in der zweiten Studie aber vor allem gezeigt, dass domänenspezifische IIV weder in 
LKB-S noch in LKB-AKA höher war als in GKP. Obwohl es möglich ist, dass die eher kleinen 
Patientengruppen sowie die generell eher niedrige Ausprägung von IIV über Trefferquoten (Hultsch et 
al., 2000) zu diesem Resultat geführt haben könnten, ist es dennoch eher fraglich, ob 
domänenspezifische IIV tatsächlich zur Früherkennung von AK beitragen kann. 
Im Rahmen der dritten Studie wurde untersucht, ob Formveränderungen in bestimmten subkortikalen 
Hirnstrukturen zur Früherkennung von AK beitragen können. Aufgrund ihrer ausgeprägten 
Verbindungen zu anderen AK-relevanten Strukturen wie dem Hippocampus (Zarei et al., 2010) sowie 
aufgrund der frühen AK-Pathologie (Braak & Braak, 1990, 1991a) wurden der Thalamus und das 
Striatum in LKB-S, in LKB-AKA und in LKB-AKA zum Zeitpunkt der AK-Diagnose (LKB-AKD) 
untersucht. Gleichzeitig wurden bereits etablierte morphometrische Marker wie die kortikale Dicke 
und die Volumina des Hippocampus und seiner Teilbereiche erhoben und untersucht. Die 
morphometrischen Veränderungen, die sich in LKB-AKA sowie in LKB-AKD aber nicht in LKB-S 
zeigten, umfassten nicht nur ausgeprägte Formveränderungen im Thalamus und im Striatum, sondern 
vii 
 
auch ein AK-typisches Muster, bestehend aus reduzierter kortikalen Dicke in mediotemporalen 
Regionen und reduzierten Volumina sowohl im gesamten Hippocampus als auch in den meisten seiner 
Teilbereiche. Diese Resultate bestätigen den potentiellen Wert morphometrischer Veränderungen in 
subkortikalen Strukturen für die Früherkennung von AK. Gleichzeitig betonen sie die Wichtigkeit, 
regionale morphometrische Veränderungen mehrerer subkortikaler Strukturen zu berücksichtigen. 
Zusammenfassend weisen die Resultate der vorliegenden Arbeit darauf hin, dass Formveränderungen 
im Thalamus und im Striatum mögliche morphometrische Marker für die Früherkennung darstellen, 
während domänenspezifische IIV als kognitiver Marker eher fraglich ist und weiterer Untersuchungen 
bedarf. Insgesamt liefern die vorliegenden Resultate eine weitere Bestätigung für die Schlüsselrolle 
morphometrischer Marker in der Früherkennung von AK sowie Hinweise darauf, dass diese den 
kognitiven Markern überlegen sind. Die Rolle der kognitiven Marker scheint dabei aufgrund 
testbezogener Eigenschaften limitiert zu sein, insbesondere dann, wenn die Marker anlässlich eines 
einzigen Messzeitpunktes erhoben werden. 
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1 Introduction 
 
The world’s population is aging and as a direct consequence it is estimated that 44.35 million people 
worldwide currently live with dementia, reaching 75.62 million in 2030 and 135.46 million in 2050 
(Alzheimer’s Disease International, 2013). Alzheimer’s disease (AD) is the most common cause of 
dementia and is responsible for 50-70% of dementia cases (Masters, Cappai, Barnham, & Villemagne, 
2006). Clinically, AD is an incurable, disabling, and devastating neurodegenerative disorder 
characterized by progressive decline in memory and other cognitive functions ultimately leading to a 
dementia syndrome when the patient is incapable of independent living. Current treatments provide 
only symptomatic relief for a short period. Improved treatment methods that are now under 
investigation may be most efficacious in preclinical or early disease stages (Golde et al., 2011; 
Sperling, Jack, et al., 2011), referred to as mild cognitive impairment (MCI). However, the 
development of cognitive and clinical symptoms varies even in MCI. Some subjects develop dementia 
other than AD, whereas others remain stable for a long time or even recover (Roberts et al., 2014). 
Accordingly, the establishment of markers that accurately identify individuals at risk for AD 
represents a major contemporary goal in AD disease research worldwide.  
Structural magnetic resonance imaging (MRI) represents a key imaging marker for the early detection 
of AD, with hippocampal atrophy in particular being present at the earliest stages of AD (Jack et al., 
2013; Johnson, Fox, Sperling, & Klunk, 2012). However, gray matter volume alterations of a single 
structure may not necessarily be associated with AD pathology (van de Pol et al., 2006), and thus, 
might not be sufficient to characterize the progression of AD pathology across the brain. Reports of 
early AD pathology in other subcortical structures (Braak & Braak, 1990, 1991a, 1991b; Braak & Del 
Tredici, 2011) have indicated that the early detection of AD might be improved when more regional 
information about shape of further subcortical structures is taken into account. 
Likewise, episodic memory impairment represents a well-established cognitive marker for the early 
detection of AD (for an overview see Gainotti et al., 2014). However, despite extensive evidence for 
the advantageous use of cognitive markers, the reliable detection of early cognitive impairment based 
on mean cognitive performance in clinical routine still poses a challenge. In particular, the 
discrimination between impaired performance due to low educational background, daily fluctuations 
and AD-related cognitive impairment (Kliegel & Sliwinski, 2004), or the detection of subtle cognitive 
changes in general (Drago et al., 2011) complicate the identification of AD-related cognitive 
alterations.  
Both cognitive and structural markers can easily be obtained by applying non-invasive methods. 
Clinical standard MRI and neuropsychological assessments are widely available in clinical settings, 
represent financially favorable methods and pose only minimal burden to the patient. Thus, the present 
work aims to extend the knowledge about cognitive and structural measures by investigating the 
potential value of a newly developed cognitive marker and of alterations in subcortical structures as 
early markers for AD. After the introduction in chapter 1, chapter 2 will provide background  
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information about disease-related pathology, criteria for the diagnosis of AD and MCI, biomarkers for 
AD in general, and cognitive and morphometric markers in particular. The methods section in chapter 
3 will then provide information about the participants, cognitive and morphometric variables and 
applied techniques. Chapter 4 will outline the aims and research questions, followed by the empirical 
studies in chapter 5. Chapter 6 will discuss and summarize the results and will comment on 
implications and future directions. 
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2 Theoretical background 
 
2.1 Alzheimer’s disease pathology 
 
Amyloid-β (Aβ) peptides (Glenner & Wong, 1984; Masters et al., 1985) and hyper-phosphorylated tau 
protein (Mandelkow, Von Bergen, Biernat, & Mandelkow, 2007) represent the main components of 
extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT), both representing major 
histopathological hallmarks of AD (Jellinger, 1990). In the predominant amyloid cascade hypothesis, 
Aβ in particular has been assumed to represent the trigger for AD (Hardy & Selkoe, 2002). More 
precisely, it has been suggested that the discrepancy between production and decomposition of Aβ 
might result in the production of plaque, and eventually of NFT, followed by neuronal dysfunction, 
degeneration and clinical symptoms (Hardy, 2009).  
Concurrently, NFT has moved increasingly into focus as a potentially responsible trigger of AD 
pathology. Specifically, it has been assumed that abnormally phosphorylated tau (p-tau) impairs 
axonal transports and leads to intraneuronal aggregation of NFT, synaptic dysfunction, and neuronal 
loss (Walker, Diamond, Duff, & Hyman, 2013). Moreover, the pattern of NFT formation has been 
suggested to better reflect AD-typical atrophy patterns. Thus, and similar to atrophy patterns (Tondelli 
et al., 2012; Whitwell et al., 2012), early NFT has been identified in perirhinal and entorhinal cortices 
with further extension to hippocampal and other mediotemporal regions, followed by the involvement 
of neocortical association areas of the temporal, parietal and frontal lobes (Braak & Braak, 1991b). 
Primary sensory areas, however, have been found to be involved only in later disease stages (Braak & 
Braak, 1995). Outside the cerebral cortex, the earliest and most severe NFT has been identified in 
anterior thalamic regions (Braak & Braak, 1991a, 1991b) with the striatum being spared until later 
disease stages (Braak & Braak, 1990, 1991b). In contrast, Aβ depositions have been shown to follow a 
different pattern, with early depositions in the basal frontal, temporal and occipital lobe and 
subsequent expansion to the striatum and cholinergic nuclei of the basal forebrain (Braak & Braak, 
1991b; Thal, Rüb, Orantes, & Braak, 2002). Thalamic subnuclei have been involved later and less 
severely (Braak & Braak, 1991a, 1991b), followed by cerebellar Aβ deposition, and with hippocampal 
regions being only mildly involved for a long time (Braak & Braak, 1991b). Accordingly, it has been 
assumed that Aβ aggregation represents an early and necessary, though not sufficient, pathological 
feature leading to cognitive impairment in AD (Reitz, 2012). 
Although the role of Aβ and tau, and the exact mechanisms that trigger and promote 
neurodegeneration in the brain remain to be fully understood, Aβ- and tau-related measures are still in 
the focus of AD researchers in the quest for markers for the early detection of AD. Consequently, their 
presence increases the likelihood of AD diagnosis in the current diagnostic recommendations for 
probable AD. 
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2.2 Diagnostic criteria for Alzheimer’s disease 
 
The criteria for the diagnosis of probable AD were established by the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS–ADRDA) in 1984 (McKhann et al.). Mainly due to advances in 
methods allowing for the reliable detection of Aβ and tau, NINCDS-ADRDA criteria were reviewed 
in 2011. Briefly, the current criteria for the diagnosis of probable AD (McKhann et al., 2011) require 
the presence of a decline in cognitive or behavioral functioning involving at least two of five domains 
(memory, executive functions, visuospatial abilities, language, personality), significantly interfering 
with the patient’s ability to perform activities of daily living. Furthermore, insidious symptom onset as 
well as early and most pronounced deficits in memory and in at least one other cognitive domain must 
be met. Clinically significant cerebrovascular disease, features of other forms of dementia, or any 
other active comorbidity that might have caused cognitive worsening must be absent. Evidence of a 
disease-relevant genetic mutation further increases the certainty of AD diagnosis. Markers showing 
amyloid deposition in the brain (positron emission tomography [PET] amyloid imaging) or reduced 
Aβ in cerebrospinal fluid (CSF) (lumbar puncture), or neurodegeneration indicated by reduced glucose 
metabolism (18F-Fluordesoxyglucose [FDG]-PET), increased gray matter atrophy (structural MRI) or 
increased tau in CSF further increase the confidence of AD-related pathology accounting for the 
dementia syndrome. It has to be noted, however, that the application of these pathological markers for 
diagnostic purposes in the current criteria were mainly considered for research but not clinical use. 
This was for methodological reasons such as limited availability of some of the involved methods and 
the lack of standardizations and cut-off values at that time (McKhann et al., 2011). 
 
2.3 Early detection of Alzheimer’s disease 
 
2.3.1 Mild cognitive impairment  
 
MCI refers to the transitional zone between normal aging and AD (Petersen, 1995). Although memory 
deficits represent the hallmark of MCI, cognitive impairments in general must not be sufficient to 
affect activities of daily living (Petersen, 2004; Petersen et al., 2001; Winblad et al., 2004). Results 
from longitudinal studies have shown an increased risk for MCI patients to develop dementia within a 
few years (Gallagher et al., 2010; Petersen, 2004), and MCI has therefore been recognized as a risk 
state for dementia (Gauthier et al., 2006). Four different subtypes have been distinguished (Petersen, 
2004; Petersen et al., 2001; Winblad et al., 2004): isolated memory impairment (amnestic single 
domain, aMCIs), impairment in memory and other cognitive domains (amnestic multiple domain, 
aMCIm), impairment in a single non-memory domain (non-amnestic single domain, nMCIs) or  
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impairment in more than one non-memory domain (non-amnestic multiple domain, nMCIm). Of the 
proposed subtypes, amnestic MCI (aMCI) in general, and aMCIm in particular have demonstrated a 
higher probability of progressing to AD (e.g. Roberts et al., 2014). In contrast, non-amnestic subtypes 
have been identified as prodromal states for non-AD dementias (Bäckman, Jones, Berger, Laukka, & 
Small, 2005; Mitchell & Shiri-Feshki, 2009).  
Nevertheless, there has been heterogeneity with regard to the longitudinal development of cognitive 
abilities and other clinical symptoms. The annual conversion rates from aMCI to AD vary from 4% to 
20% (Dickerson, Sperling, Hyman, Albert, & Blacker, 2007; Landau et al., 2010; Maioli et al., 2007; 
Mitchell & Shiri-Feshki, 2009; Rabin et al., 2009; Schmand, Eikelenboom, & van Gool, 2012; Tabert 
et al., 2006), with lower rates in population-based samples, and higher rates in clinical samples. 
Accordingly, there is a considerable proportion of aMCI whose cognitive abilities remain stable over 
long periods of time (Fisk, Merry, & Rockwood, 2003; Mitchell & Shiri-Feshki, 2009; Roberts et al., 
2014) or even recover (Forlenza et al., 2009; Roberts et al., 2014). When compared to healthy control 
subjects (HCS), the risk for conversion to AD has recently been found to be higher in MCI who had 
reverted back to normal cognitive abilities at least once (Roberts et al., 2014). Less is known about the 
long-term development of cognitive functions in MCI with stable cognitive abilities. Some authors 
have referred to this stage as a potential early stage of AD (Bossa, Zacur, & Olmos, 2011) whereas 
others have just referred to a long-lasting diagnostic stability (Bakkour, Morris, & Dickerson, 2009; Li 
et al., 2012; Tang et al., 2014). These results emphasize the heterogeneous long-term development of 
cognitive abilities in MCI, complicating the identification of future converter subjects.  
 
2.3.1.1 Diagnostic criteria for Mild cognitive impairment  
 
The current criteria provide recommendations not only for MCI due to AD (Albert et al., 2011), but 
also for preclinical AD (Sperling, Aisen, et al., 2011). Preclinical AD is diagnosed in the presence of 
Aβ deposition and/or neurodegeneration and the simultaneous absence of clinical symptoms such as 
memory impairment. In contrast, MCI due to AD is diagnosed in the presence of cognitive decline, 
evidence of impairment in one or more cognitive domains but preserved functional abilities and no 
dementia diagnosis. Although there is no differentiation between subtypes, it has been noted that 
memory impairment is commonly present in future converters (Albert et al., 2011). If information 
about AD pathology is available, MCI due to AD are additionally required to reveal either a positive 
biomarker reflecting Aβ deposition or neurodegeneration. If one biomarker is positive, there is an 
intermediate likelihood of future conversion to dementia whereas the likelihood is high for subjects 
with both biomarkers being positive. MCI is unlikely to be due to AD if both biomarkers are negative. 
Nevertheless, and for similar reasons as described in section 2.2, the use of AD markers has mainly 
been proposed for research settings.  
Importantly, by establishing the presence of AD pathology already in preclinical stages of AD, the 
current incorporation of AD markers emphasizes the suggestion that AD pathology represents a 
continuum (Sperling & Johnson, 2013). 
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2.3.2 Biomarker  
 
Biomarkers are biological factors that can be measured and represent the presence or absence of 
pathophysiological processes (Alzheimer’s Association, 2014). In the case of AD, pathophysiological 
processes involving Aβ and tau have been shown to be present 20 years or more before clinical 
symptoms occur (Jack et al., 2009; Reiman et al., 2012; Villemagne et al., 2013). Thus, biomarkers 
play a crucial role in the early detection and diagnosis of AD. Acknowledging this fact, the five most 
widely studied biomarkers of AD have been incorporated into the current diagnostic criteria (Albert et 
al., 2011; McKhann et al., 2011; Sperling, Aisen, et al., 2011). Moreover, these biomarkers have been 
integrated into a hypothetical model (Jack et al., 2013) that assumes that AD biomarkers become 
abnormal in a temporally ordered way (Jack et al., 2009; Mormino et al., 2009; Perrin, Fagan, & 
Holtzman, 2009). The model, therefore, provides useful information for improving the early detection 
of AD. 
In particular, and referring to previous research, the model assumes that markers of Aβ accumulation 
become abnormal first, with CSF Aβ becoming atypical slightly before amyloid PET imaging. 
Markers of neurodegeneration become abnormal later, with CSF tau levels becoming atypical first 
(e.g. Braak, Zetterberg, Del Tredici, & Blennow, 2013; Buchhave et al., 2012), followed by MRI and 
FDG-PET. However, based on results from autopsy studies (Braak & Del Tredici, 2011), the model 
also proposes that tau pathophysiology might appear in subcortical regions very early, with Aβ 
pathophysiology starting later and independently (Jack et al., 2013). Initial subcortical tauopathy, 
however, can only be detected by using immunostaining methods but may accelerate the preceding 
subcortical tauopathy (Musiek & Holtzman, 2012; Price & Morris, 1999). The model furthermore 
assumes a strong relationship between neurodegenerative markers and cognitive performance in MCI 
and AD (Jack et al., 2000; Vemuri et al., 2010) but a weak relationship between Aβ markers and 
cognitive performance (Jack et al., 2008; Jack et al., 2009; Lim et al., 2013). Importantly, the model 
has also posits that factors such as age, genetics, and education in particular are most likely 
responsible for differences in the time lag between beginning Aβ accumulation and the onset of 
clinical symptoms. 
This model has gained a lot of attention, and since then, many biomarker studies have been performed 
to further evaluate the biomarkers themselves and the model’s assumptions. However, several 
drawbacks to these AD biomarkers need to be considered. As mentioned in previous sections, there is 
a lack of well validated and accepted normative and cut off values for most biomarkers (Sperling & 
Johnson, 2013). With regard to CSF measures in particular, high variation between centers due to 
variations in assays pose a challenge (Forlenza, Diniz, Teixeira, Stella, & Gattaz, 2013). Furthermore, 
the collection of CSF by lumbar puncture remains invasive and has been associated with health risks. 
With respect to amyloid PET imaging, it remains unknown whether there is a threshold or cut off 
value at which the tracer uptake represents a pathological signal (Sperling, Aisen, et al., 2011). 
Furthermore, the presence of amyloid deposition in the brain does not necessarily establish AD as this  
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has also been found in other neurodegenerative diseases such as Lewy body dementia (Mulugeta et al., 
2011) or frontotemporal dementia (Perneczky et al., 2011), but also in HCS (Villemagne et al., 2011). 
Importantly, the clinical applicability of amyloid PET imaging is reduced due to limited registration as 
a diagnostic tool, high costs, and the application of radioactive tracers posing a burden to the patient.   
Consequently, more work is needed to establish reliable thresholds and cut offs for well-known 
biomarkers on the one hand, and to investigate the potential of further biomarkers that can be 
implemented in clinical settings on the other hand.  
 
2.3.3 Morphometric markers  
 
According to the previously introduced biomarker model from Jack et al. (2013), structural MRI 
markers represent rather late occurring biomarkers. Nevertheless, structural MRI has become a key 
imaging marker for the early detection of AD, and the comparison of regional brain volumes across 
groups of HCS, MCI and AD represents the most established approach in AD research. Brain atrophy 
has been associated with NFT (Yushkevich et al., 2014) and cognitive impairment (Ferrarini et al., 
2014), and its regional pattern has been shown to correspond with the pattern of progressing NFT in 
AD (see section 2.1). Here, a short overview of the most established structural MRI markers for AD 
will be provided. Given the relevance of gray matter alterations in AD, the focus will be on measures 
providing global or regional information about changes in gray matter structures (hereafter referred to 
as morphometric measures). Subsequently, a recently developed marker that might further support the 
early detection of AD will be introduced.  
 
2.3.3.1 Established morphometric markers 
 
So far, most researchers have focused on measuring mediotemporal atrophy. Atrophy of the 
hippocampus and entorhinal cortex in particular has been demonstrated early in the AD disease course 
(e.g. Tapiola et al., 2008; Tondelli et al., 2012). Hippocampal shrinking represents the key imaging 
marker for AD (Cummings, Dubois, Molinuevo, & Scheltens, 2013) and has been incorporated in the 
current research criteria for MCI (Sperling, Aisen, et al., 2011) and AD (Albert et al., 2011). Results 
from histology studies have indicated that hippocampal subfields are affected differently by 
neurofibrillary tangle formation, with the earliest and most prominent involvement of cornu ammonis 
(CA)1 followed by the subiculum, and later involvement of CA2 and CA3 (Braak & Braak, 1991b; 
Braak, Braak, & Bohl, 1993; Rossler, Zarski, Bohl, & Ohm, 2002). Corresponding atrophy patterns 
have recently been found in MCI (Apostolova, Dinov, et al., 2006; Atienza et al., 2011; La Joie et al., 
2013; Pluta, Yushkevich, Das, & Wolk, 2012; Yushkevich et al., 2014) and AD (Apostolova, Dinov, 
et al., 2006; Frankó, Joly, & the Alzheimer’s Disease Neuroimaging Initiative, 2013; Frisoni et al., 
2008; Li, Dong, Xie, & Zhang, 2013). Local analysis of the structure, therefore, has been viewed as 
advantageous for the early detection of dementia (Maruszak & Thuret, 2014; Tang et al., 2014). 
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Volumes of other subcortical nuclei have received less attention, and results about volume reductions 
in AD have been mixed. Atrophy in the amygdala, putamen, caudate, and thalamus have indeed been 
identified in AD (Cho et al., 2014; de Jong et al., 2014; Stepan-Buksakowska et al., 2014; Tang et al., 
2014). Others, however, could not identify comparable atrophy in AD (Cho et al., 2014; Stepan-
Buksakowska et al., 2014). Importantly, similarly mixed results have been reported with regard to 
subcortical atrophy in MCI (Bossa et al., 2011; Leh et al., 2014; Tang et al., 2014; Zhang et al., 2013). 
Cortical thickness analysis has been suggested to represent a more sophisticated way to measure brain 
atrophy (Lerch & Evans, 2005) and thus constitutes another widely accepted approach to assess gray 
matter atrophy in AD. Specifically, cortical thinning has been found in patients with MCI and AD 
(Lerch, Pruessner, et al., 2008; Liao et al., 2014), in future converters when compared to healthy 
controls (Liao et al., 2014), and to predict conversion to AD in MCI (Querbes et al., 2009). Typically, 
AD-associated cortical thinning has been identified in temporal and medial temporal, lateral parietal 
and frontal cortices, as well as in the limbic system (Bakkour et al., 2009; Dickerson et al., 2009; 
Lerch, Pruessner, et al., 2008; Li et al., 2012; Liao et al., 2014; Peters, Villeneuve, & Belleville, 2014; 
Ye et al., 2014).  
Although gray matter alterations assessed by MRI represent valuable biomarkers for AD, hippocampal 
atrophy in particular has shown only moderate specificity as it has also been seen in normal aging 
(Apostolova et al., 2012), in hippocampal sclerosis (Dawe, Bennett, Schneider, & Arfanakis, 2011) 
and in other forms of dementia (de Souza et al., 2013; La Joie et al., 2013; Tondelli et al., 2012). 
Moreover, by taking into account the progressing pattern of AD pathology across the brain (see 
section 2.1), the appropriate characterization of AD might require the consideration of multiple 
structures. Additionally, as results from hippocampal subfield analyses have indicated, more local 
information about different structures might further contribute to the characterization of AD-typical 
patterns of morphometric alterations.  
 
2.3.3.2 Subcortical alterations 
 
The thalamus and the striatum in particular represent structures that might be of high value for the 
early detection of AD for many reasons. More precisely, the thalamus consists of different subnuclei, 
with anterior subnuclei in particular being affected by AD pathology very early (Braak & Braak, 
1991a, 1991b). Furthermore, the structure is highly connected with other AD-relevant structures such 
as the hippocampus (Zarei et al., 2010) and has been linked with memory, attention, visuospatial 
perception, and emotion processing (Arend, Henik, & Okon-Singer, 2014; de Bourbon-Teles et al., 
2014; Saalmann, 2014; Wilke, Kagan, & Andersen, 2013), and hence, with AD-related cognitive 
impairment. The neostriatum consisting of the putamen and caudate nucleus (hereafter referred to as 
striatum) in turn has revealed NFT at rather late histopathological disease stages (Beach et al., 2012; 
Braak & Braak, 1990, 1991b; Thal et al., 2002). Similar to the thalamus, however, the striatum has  
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been linked to a wide range of cognitive functions such as attention, planning and memory 
(Cummings, 1995), all representing functions that are impaired early in AD (Klekociuk, Summers, 
Vickers, & Summers, 2014). The possibility of early AD-related alterations in these structures is 
therefore highly likely. Due to improvements in segmentation and analysis techniques, recent results 
have indeed provided evidence for alterations in the thalamus (Roh et al., 2011; Stepan-Buksakowska 
et al., 2014; Zarei et al., 2010), putamen (Cho et al., 2014; de Jong et al., 2014; Roh et al., 2011), and 
caudate nucleus (Cho et al., 2014; Madsen et al., 2010; Roh et al., 2011) in AD. However, less is 
known about subcortical volumetric and shape differences in MCI in general, and in future converters 
in particular.  
 
2.3.4 Cognitive markers  
 
A large number of studies have evidenced a long period and slow rate of cognitive decline that may 
occur up to a decade before MCI or AD have been diagnosed (e.g. Amieva et al., 2014), with a period 
of more rapid deterioration and more pronounced deficits several years before the clinical onset of 
MCI (Howieson et al., 2008). Thus, cognitive markers have demonstrated the potential as early 
markers for AD. 
 
2.3.4.1 Established cognitive markers 
 
Impaired memory functions including deficits in episodic and semantic memory functions represent 
cognitive hallmarks of AD that have repeatedly been found in healthy elderly subjects who later 
developed dementia, as well as in MCI and in AD patients (for an overview see Gainotti et al., 2014). 
Delayed recall deficits in particular have reliably predicted conversion to AD in MCI. 
Similarly, deficits in executive functions have been well documented in both MCI and AD patients 
(e.g. da Costa Armentano, Porto, Nitrini, & Dozzi Brucki, 2013), and have been shown to predict 
conversion to AD in  healthy elderly subjects (Wilson, Leurgans, Boyle, & Bennett, 2011). 
Furthermore, corresponding declines have been found up to three years before AD onset (Grober et al., 
2008). In particular, performances on tasks assessing working memory (Amieva et al., 2004; Brandt et 
al., 2009; Wilson et al., 2012), task switching (Chen et al., 2000; da Costa Armentano et al., 2013; 
Dickerson et al., 2007), inhibitory control (Amieva et al., 1998; Rainville et al., 2002), cognitive 
flexibility and cognitive control (Rapp & Reischies, 2005; Schroeter et al., 2012) as well as problem 
solving and planning (Brandt et al., 2009; da Costa Armentano et al., 2013) have represented early 
clinical signs.  
Deficits in other cognitive domains such as language, attention and visuospatial functions have also 
been reported in MCI (Belleville, Chertkow, & Gauthier, 2007; McLaughlin, Anderson, Rich, 
Chertkow, & Murtha, 2014; Taler & Phillips, 2008), with more pronounced deficits in AD (Chen et 
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al., 2001; Tsantali, Economidis, & Tsolaki, 2013; Vasquez et al., 2011). However, their consideration 
is mainly of high importance for the identification of MCI not due to AD, with prominent attentional, 
visuospatial or language deficits representing hallmarks for Lewy body dementia (McKeith et al., 
2005), posterior cortical atrophy (Mendez, Ghajarania, & Perryman, 2002) and primary progressive 
aphasia (Gorno-Tempini et al., 2011), respectively.  
These encouraging results, however, conceal the fact that the reliable detection of early cognitive 
impairment in clinical routine still poses a challenge. The lack of a standard use of cognitive tests, and 
of tests that allow the valid and reliable assessment of particular cognitive functions or even subtle 
cognitive alterations in, for example, highly educated subjects hamper the identification of early 
cognitive impairment. Additionally, there is no uniformly accepted cut-off for the definition of 
cognitive impairment. Therefore, there is a need to identify cognitive markers that enable the detection 
of the earliest cognitive alterations even in the absence of objective impairment on standardized 
testing.  
 
2.3.4.2 Intraindividual variability in cognitive performance 
 
Intraindividual variability (IIV) in cognitive performance has been found to represent a potentially 
more sensitive early marker of cognitive impairment (Dixon et al., 2007; MacDonald, Hultsch, & 
Dixon, 2008), and might overcome some of the above-mentioned limitations that have been associated 
with standardized testing. IIV has been recognized as a stable trait reflecting central nervous system 
pathology (Hultsch et al., 2000) and can be defined as behavioral changes that may occur quickly and 
over relatively short time frames (Nesselroade, 1991). IIV across multiple trials of a single reaction 
time task or across different reaction time tasks assessed on one occasion (latency-based IIV) have 
been shown to be increased in MCI (Christensen et al., 2005; Dixon et al., 2007; Duchek et al., 2009; 
McLaughlin, Borrie, & Murtha, 2010; Phillips, Rogers, Haworth, Bayer, & Tales, 2013; Strauss, 
Bielak, Bunce, Hunter, & Hultsch, 2007) and AD (Hultsch et al., 2000; Jackson, Balota, Duchek, & 
Head, 2012; Phillips et al., 2013; Rochat et al., 2013). The implementation of latency-based IIV 
measures in clinical routine, however, is complicated by the requirement to integrate repeatedly 
applied reaction time tasks in already comprehensive neuropsychological test batteries. Additional and 
repeatedly applied tests might further increase the burden for these already stressed patients. 
IIV computed across the accuracy scores (accuracy-based IIV) obtained from different widely 
established cognitive tests has, therefore, offered an alternative approach. Although accuracy-based 
IIV has not been investigated extensively in AD, results have been promising for predicting incident 
dementia (Holtzer et al., 2008) and probable AD (Vaughan et al., 2013).  
With regard to neural correlates, IIV has been proposed to index neurobiological disturbance (Hultsch, 
Strauss, Hunter, & MacDonald, 2008) and failure to maintain cognitive control (West et al., 2002). 
Cognitive control processes and IIV are thought to be supported by dorsolateral and ventrolateral 
prefrontal cortices (dlPFC; vlPFC) (Levy & Wagner, 2011; Liston et al., 2006) and parietal cortex 
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regions (PCC) (Wilk et al., 2012). Only a few studies have examined structural correlates of accuracy-
based IIV in general, but results provide support for an association between reduced prefrontal gray 
matter volume and higher IIV in healthy older adults (Lövdén et al., 2013).  
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3 Methods 
 
3.1 Participants 
 
The studies included in the present work were performed by merging the baseline and follow-up data 
of elderly subjects that were enrolled in three different and still on-going longitudinal as well as one 
cross-sectional study located at the Memory Clinic at the Division of Psychiatry Research and 
Psychogeriatric Medicine, University of Zurich. The primary aim of all studies was to identify risk 
factors for dementia.  
Briefly, participants were recruited from the outpatient population of the Memory Clinic or through 
advertisements in the local media. HCS were additionally recruited through inquiries of caregivers or 
relatives of the patients. All diagnoses were made by a multidisciplinary team under the supervision of 
an experienced psychiatrist and according to Winblad criteria for MCI (Winblad et al., 2004), and 
NINCDS-ADRDA criteria for AD (McKhann et al., 2011). Details about inclusion and exclusion 
criteria will be provided in the empirical part (chapter 5).  
Visits of the longitudinal studies were scheduled every 12 to 18 months. MCI subjects classified as 
critical for conversion to dementia received additional 6 months screenings. Baseline and follow up 
visits of the longitudinal studies included: screenings for depression including Hamilton Rating Scale 
for Depression (Hamilton, 1960) or Hospital Anxiety and Depression Scale-Deutsche Version 
(HADS-D) (Herrmann-Lingen, Buss, & Snaith, 2011), screening for cognitive functioning Clinical 
Dementia Rating Scale (CDR) (Morris, 1993), cognitive disorder Mini-Mental State Examination 
(MMSE) (Folstein, Folstein, & McHugh, 1975), comorbidity Cumulative Illness Rating Scale (CIRS) 
(Salvi et al., 2008), and Instrumental Activities of Daily Living (IADL) (Lawton & Brody, 1969) as 
well as psychiatric, neurological and internal diseases, and other disorders that could potentially 
produce cognitive impairment. MRI data were assessed in two of the studies, and scans were 
performed at baseline and follow up visits. Amyloid-PET imaging with the 11(C)-Pittsburgh 
compound B was performed in one study at baseline and at three year follow up visits. 
All studies were approved by the cantonal ethics committee of canton Zurich, Switzerland. Subjects 
were only included after providing written informed consent. Details about the identification of 
subsamples relevant for the present work will be provided in the empirical part (chapter 5). 
 
3.2 Neuropsychology 
 
The neuropsychological test battery was administered at baseline and follow up visits. Apart from the 
CERAD-plus test battery (Thalmann et al., 1997), the following tests were applied to evaluate five 
cognitive domains: Verbaler Lern- und Merkfähigkeitstest (VLMT) (Helmstaedter, Lendt, & Lux, 
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2001), nonverbal and verbal Paired Associates test (Wechsler Memory Scale-Revised [WMS-R]) 
(Härting et al., 2000), and recall of the Rey-Osterrieth Complex Figure (ROCF) (Meyers & Meyers, 
1995) for verbal and nonverbal memory functions; category and letter fluency (Aschenbrenner, Tucha, 
& Lange, 2000), Five-Point Test (Regard, Strauss, & Knapp, 1982), Stroop interference score (Troyer, 
Leach, & Strauss, 2006), Trail Making Test (TMT) ratio B/A (Reitan, 1958), Visual and Verbal 
Memory Span backward (WMS-R) (Härting et al., 2000) for executive functions; TMT A and B 
(Reitan, 1958), Visual and Verbal Memory Span forward (WMS-R) (Härting et al., 2000) for attention 
and psychomotor speed; Boston Naming Test (BNT) (Thalmann et al., 1997) for language abilities; 
Clock Drawing Test (Rouleau, Salmon, Butters, Kennedy, & McGuire, 1992) and copy of  the ROCF 
for visuo-constructive and visuo-spatial abilities. Impairment was defined if at least one score per 
domain was 1.5 standard deviations (SD) below group means provided by test-specific normative data. 
 
3.3 Intraindividual variability 
 
Based on the few but promising results obtained from studies examining accuracy-based IIV in AD 
research (see section 2.3.4.2), the potential value of two different accuracy-based IIV scores as early 
markers for AD was examined. On the one hand, based on other studies (Brewster, Tuokko, & 
MacDonald, 2012; MacDonald, Brewster, Laukka, Fratiglioni, & Bäckman, 2012; Tractenberg & 
Pietrzak, 2011), IIV was calculated across accuracy scores obtained from cognitive tests assessing 
different cognitive domains each (across-domain IIV). On the other hand, based on the assumption of 
a close relationship between IIV and cognitive control processes supported by the frontal cortex 
(MacDonald, Li, & Bäckman, 2009), IIV was calculated across accuracy scores obtained from three 
tests, each eliciting recruitment of cognitive control processes (within-domain IIV). Further details 
about the identification of relevant tasks will be provided in the empirical part (chapter 5). 
IIV can be computed in different ways. The simplest method is to compute the mean intraindividual 
standard deviation (ISD) across each individual’s standardized performance scores (Slifkin & Newell, 
1998), with higher standard deviations indicating higher IIV. A disadvantage of ISD, however, is its 
dependence on the mean (Nesselroade & Salthouse, 2004). In particular, increased IIV in reaction time 
tasks may reflect increased mean performance and thus, poorer performance (Hale, Myerson, Smith, 
& Poon, 1988) whereas in non-speeded tasks, increased IIV may be associated with higher 
performance (Allaire & Marsiske, 2005). Accordingly, this may result in increased accuracy-based IIV 
in HCS due to their higher mean performance.  Mean performance and ISD may furthermore be 
artificially correlated due to floor and ceiling effects, with extreme performers showing smaller IIV 
(Baird, Le, & Lucas, 2006). Thus, individual mean performances represent a potential confounder and 
need to be considered when examining IIV scores. In the context of the present work, each 
individual’s mean performance was considered as a covariate in all relevant analyses. More detailed 
information about the calculation of IIV will be provided in the empirical part (chapter 5, study 1 and 
2). 
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3.4 Structural magnetic resonance imaging 
 
A full description of the complex physical principles on which structural MRI is based is beyond the 
scope of this work. Briefly, the imaging of brain structures is based on the magnetic characteristic of 
hydrogen atoms in the human brain as well as the radio frequency signal and its decay after having 
been exposed to the static magnetic field of the scanner and temporarily applied radio frequency 
electromagnetic pulses (Weishaupt, Köchli, & Marincek, 2006). Different tissue types can then be 
distinguished based on different magnetization properties. Due to its high contrast, T1 weighted data 
in particular allows the differentiation of gray matter, white matter and CSF. 
The manual delineation of human neuroanatomical structures on T1 weighted data still represents the 
gold standard for the identification of brain structures. The enormous time investment as well as high 
inter- and intra-rater variability (Chakravarty, Sadikot, Germann, Bertrand, & Collins, 2008; 
Chakravarty et al., 2009), however, represent substantial drawbacks and have supported the 
development of fully automated segmentation methods. The present work involves well-known, 
sophisticated, and fully automated methods for the assessment of established AD biomarkers such as 
hippocampal and hippocampal subfield volumes as well as cortical thickness. Furthermore, in order to 
investigate alterations in subcortical structures as potential early markers for AD, recently developed 
and fully automated methods were used to assess the volume and shape of the thalamus and striatum. 
For all of the subsequently described analyses, three-dimensional (3D) T1-weighted structural data 
obtained from a 1.5 Tesla scanner was converted into MINC before being used as input. The 
conversion to MINC was performed by using the RMINC toolkit (R for Medical Imaging NetCDF; 
https://github.com/Mouse-Imaging-Centre/RMINC), an image analysis software library developed for 
the R statistical environment (http://www.r-project.org). 
 
3.4.1 Subcortical segmentation 
 
The recently developed MAGeT (Multiple Automatically Generated Templates) Brain algorithm 
(Chakravarty et al., 2013) was used for the segmentation of the striatum, the thalamus and its 
subnuclei as well as the hippocampus and its subfields. 
MAGeT Brain is a multi-atlas based segmentation approach that extends standard atlas-based 
segmentations by automatically generating multiple templates within the dataset of interest from a 
minimal number of manually labelled brains. This has the added benefit of growing, through 
automated processes, the number of candidate segmentations available for any single subject. The 
method has shown improved segmentation of subcortical structures over standard atlas-based 
segmentation techniques. More precisely, increased segmentation accuracy is achieved by distributing 
random errors due to anatomical differences, registration, and resampling across the template library. 
Importantly, MAGeT has demonstrated reliability when compared with manual delineations of the 
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striatum and the thalamus (Chakravarty et al., 2013). With respect to the hippocampus and its 
subfields, MAGeT Brain has recently shown reliability in the identification of the subfields based on 
T1-weighted images obtained from a 1.5 Tesla system, and that it performs comparably, if not better 
than other established methods (Pipitone et al., 2014).  
For the segmentation of the striatum and the thalamus, MAGeT uses a single atlas derived from a set 
of 84 serial histological and manually segmented slices (Chakravarty, Bertrand, Hodge, Sadikot, & 
Collins, 2006). The atlas contains definitions for 108 anatomical regions including basal ganglia and 
thalamic structures (Gloor, 1997; Hirai & Jones, 1989; Schaltenbrand & Wahren, 1977). Segmentation 
of the hippocampus and its subfields is based on five high-resolution atlases previously developed and 
validated for use with MAGeT Brain (Pipitone et al., 2014; Winterburn et al., 2013).  
Briefly, MAGeT Brain first uses a regular atlas-based segmentation procedure to create a template 
library, which customizes the above-mentioned atlases to a subset of subjects that are distributed with 
respect to age, sex and disease category. To this end, the algorithm uses a region-of-interest based 
nonlinear transformation scheme (Chakravarty et al., 2008; Chakravarty et al., 2009) to match each 
input atlas to each subject in the template library. As previously demonstrated (Chakravarty et al., 
2013; Park et al., 2014; Pipitone et al., 2014), the use of 21 templates is optimal to account for 
neuroanatomical variability within the sample, and averaging of possible random errors. The newly 
segmented set of subjects now acts as a template library. As a second step, MAGeT generates multiple 
segmentations for each subject from the newly developed template library by using estimates of all 
pairwise nonlinear transformations. Here, the number of candidate segmentations per subject equals: 
number of atlases used x number of subjects in the template library (21). Lastly, MAGeT applies a 
voting procedure over all candidate segmentations (Collins & Pruessner, 2010), where the most 
frequently occurring label at each voxel is kept for the final segmentation output.  
 
3.4.2 Surface-based shape analysis 
 
Shape analysis allows for three-dimensional quantification of inward (contractions) and outward 
(expansions) movements on the surface, and therefore provides additional and more localized 
information regarding the previously segmented structures. Since the surface-based methodology used 
here is still under development, measures for the hippocampus are not available at the current time. In 
the present work, shape analyses of the thalamus and the striatum was performed using an adapted 
surface-based methodology, as in previous studies (Lerch, Carroll, et al., 2008; Magon et al., 2014; 
Raznahan et al., 2014; Shaw, Sharp, et al., 2014).  
First, surface-based representations of the segmented structures are created on the input atlas and 
estimated using the marching cubes algorithm (Lerch, Carroll, et al., 2008). Second, the 21 nonlinear 
portions of the transformations that map each subject to the input atlas are combined and then 
averaged across the template library. This procedure has the benefit of reducing the effects of noise 
and error, and of increasing precision and accuracy (Dorr, Lerch, Spring, Kabani, & Henkelman, 2008; 
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Frey et al., 2011). Third, global linear effects not originally accounted for in the initial linear 
transformations are further modeled and removed. This ensures that the contributions of overall 
differences in brain volume are minimized (Lerch, Carroll, et al., 2008; Raznahan et al., 2014). Fourth, 
the dot product between the nonlinear deformation vector (of the inverse of the averaged atlas-to-
subject transformation) and the surface normal at each vertex (a unit vector describing the direction 
perpendicular to the surface) is calculated. This measure provides an estimate of the local measure of 
contractions or expansions along the normal (Lerch, Carroll, et al., 2008). Fifth, surface area values are 
blurred with a 5mm surface-based diffusion smoothing kernel (Chung et al., 2003). All contractions 
and expansions, measured in millimeters, are then computed using the structures as defined in the 
subcortical atlas (Chakravarty et al., 2006) as a reference. 
 
3.4.3 Cortical thickness and cortical gray matter volumes 
 
Cortical thickness measures the thickness of the cortical band encompassing the layers of gray matter. 
More precisely, the border between gray matter and CSF (gray matter surface) and the border between 
white matter and gray matter (white matter surface) represent the outer and inner surfaces, and cortical 
thickness is measured as the distance in millimeters between these surfaces. Different fully automated 
approaches have been developed (e.g. MacDonald, Kabani, Avis, & Evans, 2000), with varying 
degrees of precision in terms of defining corresponding points on the two surfaces (Lerch & Evans, 
2005). 
For the present analyses, the CIVET pipeline (version 1.1.10; Montreal Neurological Institute at 
McGill University, Montreal, Quebec, Canada) (Ad-Dab'bagh et al., 2006) was used to estimate 
cortical thickness as well as gray matter volumes of predefined cortical regions. For measuring cortical 
thickness, CIVET uses deformable models to construct the inner and outer surfaces of the cortex in 
both hemispheres (Kim et al., 2005). Briefly, the surface deformation algorithm first fits the white 
matter surface and is then expanded towards the gray matter surface. Thus, white matter vertices are 
closely linked to their complements of the gray matter surface, and cortical thickness is then measured 
as the distance between the two surfaces at these linked vertices (Lerch & Evans, 2005). When 
compared to other methods, this definition of cortical thickness has been suggested to be the simplest 
and most precise, and to increase statistical sensitivity (Lerch & Evans, 2005). Further detail about 
particular preprocessing steps for both cortical volumes and cortical thickness will be provided in the 
empirical part (chapter 5, study 2 and 3).  
 
3.4.4 Intracranial volume 
 
The comparison of gray matter volumes across groups requires taking into account interindividual 
variability in brain morphology. Values of intracranial volume (ICV) indicate premorbid brain  
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volume, and thus are often used to adjust volumes for subsequent volume analyses. ICV has been 
shown to be larger in males than in females, to be only minimally affected by age (Buckner et al., 
2004), and to be positively correlated with gray matter volumes of cortical and subcortical brain 
structures (Barnes et al., 2010; Voevodskaya et al., 2014). When examining volume reductions in 
neurodegenerative disease, considering ICV allows for estimation of atrophy caused by 
neurodegenerative mechanisms rather than by interindividual differences in head size and brain 
morphology. 
In the present work, the FreeSurfer pipeline (version 5.1.0) was used to calculate total intracranial 
volume (eTIV) representing an estimate for ICV as described in Buckner et al. (2004). Briefly, each 
individual is registered to an atlas template (Talairach & Tournoux, 1988). The Atlas Scaling Factor 
obtained by this transformation represents the whole-brain volume adjustment that is required to 
match each individual to the atlas template and is thus used to automatically generate eTIV. This 
automated method has been shown to be equivalent to manual correction (Buckner et al., 2004) and 
has previously been used for normalization in several AD studies (Westman, Aguilar, Muehlboeck, & 
Simmons, 2013; Westman, Muehlboeck, & Simmons, 2012; Westman et al., 2011).  
There is no consensus about whether eTIV should be taken into account by using residuals from linear 
regression between raw volume and eTIV to predict adjusted volumes (Jack et al., 1998), by using 
eTIV as a covariate in regression models, or by using volumes relative to eTIV (for a discussion see 
Voevodskaya et al., 2014). In the present work, volume analyses of cortical and subcortical structures 
(chapter 5, study 2 and study 3) were performed by using raw volumes. However, all analyses were 
repeated using raw volumes relative to eTIV (volume / eTIV * 100) as described in previous studies 
examining atrophy-related volume reductions (Goto et al., 2014; Kooistra et al., 2013).  
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4 Aims and research questions 
 
The primary goal of the present work was to examine the potential of within-domain IIV as well as 
thalamic and striatal shape alterations as cognitive and morphometric markers for the early detection 
of AD. 
 
Study 1 - Aims and research questions 
The aim was to obtain more information about accuracy-based IIV in AD in general, and about within-
domain IIV in particular. This was achieved by the comparison of across- and within-domain IIV 
scores between HCS and MCI as well as AD patients, and by comparing IIV scores with each other. 
Additionally, since the APOE ɛ4 allele represents a risk factor for late-onset AD (Corder et al., 1993; 
Petersen, 1995), the relationship between IIV and APOE genotype was explored. In particular, the 
following predictions were made: 
Based on results from previous studies (MacDonald et al., 2012; Tractenberg & Pietrzak, 2011), 
across-domain IIV was expected to be higher in MCI and AD than in HCS. 
Based on the suggested relationship between cognitive control functions and IIV (MacDonald et al., 
2009) and on impaired cognitive control functions in AD (Rapp & Reischies, 2005; Schroeter et al., 
2012), within-domain IIV was also expected to be higher in MCI and AD than in HCS. 
Due to the novelty of within-domain IIV, no predictions were made regarding its comparison with 
across-domain IIV. Assuming that impaired cognitive control functions affect performances in 
different cognitive control tests to a similar extent, within-domain IIV might indeed be expected to be 
low. In contrast, tasks underlying across- domain IIV represent distinct cognitive functions that are 
most likely affected differently. Thus, IIV across these tasks might be higher than within-domain IIV. 
At the same time, however, impaired cognitive control functions might lead to highly variable 
performances across tasks in general, and across cognitive control tasks in particular. Thus, within-
domain IIV might as well be similar or even higher than across-domain IIV. 
Additionally, within-domain IIV in particular was expected to be higher in APOE ɛ4 allele carriers 
within each group. This prediction was based on the fact that the frontal lobe has not only been 
associated with cognitive control (Levy & Wagner, 2011; Liston et al., 2006) and IIV (MacDonald et 
al., 2009), but also constitutes the brain region that manifests APOE ɛ4 effects in early disease stages 
(Filbey, Chen, Sunderland, & Cohen, 2010).  
 
Study 2 - Aims and research questions 
The aim was to obtain more information about the structural correlate of within-domain IIV in AD, 
and about the value of within-domain IIV for early detection. This study, therefore, investigated the 
19 
 
relationship between within-domain IIV and gray matter volumes of IIV-relevant cortical brain 
regions in HCS, MCI with stable cognitive abilities (MCI-S) and MCI with future worsening of 
cognitive function and conversion to AD (MCI-CB). Additionally, the ability of within-domain IIV to 
predict diagnostic group membership was examined. The following predictions were made: 
Based on previously reported relationships between structural alterations in prefrontal cortex regions 
and IIV (Anstey et al., 2007; Jackson et al., 2012; Lövdén et al., 2013), a negative relationship 
between within-domain IIV and gray matter volumes of dlPFC, vlPFC and PPC was expected in MCI-
CB but not in MCI-S. 
Based on previous reports about the predictive ability of across-domain IIV (Holtzer et al., 2008) and 
the assumption that within-domain IIV represents a potentially more sensitive marker for early AD, 
within-domain IIV was expected to significantly contribute to the prediction of MCI-CB but not MCI-
S group membership. 
 
Study 3 - Aims and research questions 
The aim was to gain information about the potential value of thalamic and striatal shape alterations to 
facilitate the identification of future converters to AD. Thus, shape alterations were compared between 
HCS and MCI-S, MCI-CB and MCI-CB at time of conversion (MCI-CC). Additionally, established 
analyses techniques were used to further confirm AD-typical hippocampal atrophy and cortical 
thinning. The following predictions were made: 
AD-related neurodegenerative processes, and thus, morphometric alterations were expected in MCI-
CB with more pronounced alterations in MCI-CC. In contrast, MCI-S were expected to show only 
minimal or no alterations at all. 
Based on the pattern of NFT formation (Braak & Braak, 1990, 1991a, 1991b) and on results from 
previous studies (Cho et al., 2014; Ferrarini et al., 2014; Stepan-Buksakowska et al., 2014; Wisse, 
Biessels, Heringa, et al., 2014), volume reductions in the hippocampus, thalamus and striatum as well 
as in particular hippocampal subfields (CA1, subiculum) and thalamic (anterior) subnuclei were 
expected in MCI-CB and MCI-CC. 
Further confirming AD related atrophy and the literature (Liao et al., 2014), cortical thinning in 
mediotemporal as well as lateral cortical regions was expected in MCI-CB and MCI-CC. 
Although the neuronal basis of shape alterations is yet unknown, thalamic and striatal shape alterations 
were expected in MCI-CB and MCI-CC. On the one hand, the assumed volume reductions might lead 
to shape alterations. On the other hand, the connection with other structures showing early NFT such 
as the hippocampus (Zarei et al., 2010) might lead to secondary downstream effects and thus, shape 
alterations in the thalamus and striatum. 
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5.1.1 Abstract 
 
Recent studies have shown that increased cognitive intraindividual variability (IIV) across accuracy 
scores from tests representing different cognitive domains (across-domain IIV) might indicate 
prodromal Alzheimer’s disease (AD). Although IIV has been proposed to index cognitive control 
processes, IIV across accuracy scores from cognitive control tasks (within-domain IIV) has not been 
examined in healthy controls subjects (HCS), mild cognitive impairment (MCI) and AD patients in a 
single comparative study. This study examines the discriminative properties of within-domain IIV, and 
across-domain IIV in 149 HCS, 31 MCI and 26 AD. Three tasks representing different cognitive 
domains were identified to calculate across-domain IIV. Three other tasks representing cognitive 
control were identified to calculate within-domain IIV. The intraindividual standard deviation (ISD) 
was calculated across accuracy scores. To compare IIV between groups, ANCOVAs with the 
covariates age, gender, education, and mean performance were computed. IIV scores in general were 
higher in AD vs. HCS (p<0.01). Only across-domain IIV was higher in AD vs. MCI (p=0.001), and 
only within-domain IIV was higher in MCI vs. HCS (p=0.05). Within-domain IIV may constitute a 
cognitive marker for the detection of prodromal AD at the MCI stage, whereas across-domain IIV may 
detect beginning AD at the MCI stage. 
22 
 
5.1.2 Introduction 
 
The importance of reliable methods for the early detection of Alzheimer’s disease (AD) has increased 
with the expected availability of treatment methods, which may be most efficacious in preclinical 
(Masdeu, Kreisl, & Berman, 2012) or early disease stages (Doraiswamy et al., 2002). Cognitive 
intraindividual variability (IIV) has evidenced representing a potential marker of early cognitive 
impairment (MacDonald et al., 2009), with IIV across multiple trials of a reaction time (RT) task or 
across different RT tasks (latency-based IIV) predicting global decline (Hultsch et al., 2002; Lövden, 
Shu-Chen, Yee Lee, & Lindenberger, 2007) and being increased in mild cognitive impairment (MCI)  
(Duchek et al., 2009; McLaughlin et al., 2010) and AD (Hultsch et al., 2000; Jackson et al., 2012). 
However, integrating repetitive RT tasks into already existing comprehensive test batteries may 
increase the testing-associated burden on patients.  
Considering IIV across accuracy scores of different cognitive tasks (accuracy-based IIV) may provide 
an alternative. Although latency- and accuracy-based IIV have reportedly been associated (Hilborn et 
al., 2009; Hultsch et al., 2002), the latter has not been studied extensively. However, the use of 
accuracy-based IIV across tests representing different cognitive domains (across-domain IIV) appears 
promising for predicting global (Kliegel & Sliwinski, 2004) and functional decline (Morgan, Woods, 
& Grant, 2012), incident dementia (Holtzer et al., 2008), and probable AD (Brewster et al., 2012). 
Likewise, it was found to be increased in MCI and AD (MacDonald et al., 2012; Tractenberg & 
Pietrzak, 2011). Although IIV has been proposed to index cognitive control processes supported by the 
frontal cortex (MacDonald et al., 2009), accuracy-based IIV across tests representing cognitive control 
functions (within-domain IIV) to our knowledge has not been examined in healthy control subjects 
(HCS), MCI, and AD in a single comparative study. Consequently, the aim of our study was to 
investigate within- and across-domain IIV as markers for prodromal AD. We compared IIV between 
groups and hypothesized increased levels in MCI and AD. Additionally, and since the APOE ɛ4 allele 
represents a risk factor for late-onset AD (Corder et al., 1993; Petersen, 1995; Tang et al., 1996), we 
explored the relationship between IIV and APOE genotype.  
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5.1.3 Methods 
 
Study population 
A total of 267 subjects (HCS n=180, MCI n=44, AD n=26) from on-going studies at the Memory 
Clinic of the Division of Psychiatry Research and Psychogeriatric Medicine, University of Zurich, 
were considered for cross-sectional baseline analysis. Participants were recruited from the outpatient 
population of the Memory Clinic or by advertisement in the local media. All subjects had complete 
cognitive baseline data acquired between January 2006 and May 2012.  
MCI was diagnosed according to Winblad et al. (2004). Probable AD was diagnosed following criteria 
from National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984). All 
diagnoses were made by a multidisciplinary team under the supervision of an experienced psychiatrist. 
HCS were required to be cognitively healthy and report cognitive well-being. MCI and AD subjects 
were excluded from the present analyses if there was evidence for the use of psychoactive medication, 
abuse of alcohol and drugs, other past or present psychiatric or neurological diseases or significant 
other systemic diseases, or structural abnormalities in the brain assessed by magnetic resonance 
imaging (MRI) that could account for the cognitive decline. Additionally, HCS were excluded if there 
was significant medical disease, clinically significant depression or any medication use potentially 
affecting cognition. Visits included screenings for depression, psychiatric, neurological and internal 
diseases, and other disorders that could potentially produce cognitive impairment. The 
neuropsychological test battery consisted of multiple tests covering the following cognitive domains: 
episodic memory, executive function, attention/psychomotor processing speed, language and visual-
constructive abilities. Impairment was defined if at least one score per domain was 1.5 standard 
deviations (SD) below group means provided by test-specific normative data.  
From the original HCS sample, 31 subjects were excluded from the analyses due to clinically 
significant neurological disease (n=3), alcohol abuse (n=1), medication (n=25), and due to dropout 
after the assessment (n=2). Due to a change in test batteries, 13 MCI subjects were missing a test score 
relevant for computing IIV and were excluded from the analyses. Thus, a total of 149 HCS, 31 MCI 
patients and 26 patients with probable AD were eligible for the current analysis of IIV. The final 
demographic details are presented in Table 1. This study was approved by the cantonal ethics 
committee of canton Zurich, Switzerland, in accordance with the Helsinki Declaration. All participants 
and/or their legal representatives provided written informed consent prior to study inclusion. 
 
Computation of intraindividual variability 
Considering the clinical applicability of the IIV scores, we retrospectively identified tasks with less 
than 1% missing values per diagnostic group. Additionally, we only selected tasks with no ceiling or 
floor effects to prevent suppressing variation at the extreme ends of the distribution.  
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For calculating across-domain IIV, we used accuracy scores from three tests, each representing a 
different cognitive domain: Digit Span Forward from the Wechsler Memory Scale-Revised (Härting et 
al., 2000) assessing verbal short-term memory capacity (Lezak, Howieson, & Loring, 2004),  Word 
List Learning and Category Fluency from the CERAD-plus test battery (Thalmann et al., 1997) 
assessing verbal learning and executive function / semantic knowledge, respectively. For calculating 
within-domain IIV, we used accuracy scores from three tests, each representing executive functions 
and eliciting recruitment of cognitive control processes. The Letter Fluency test requires participants 
to name as many words as possible within 3 minutes while taking into account particular restrictions 
(i.e. no names, geographically related words, labels, repetitions). Participants need to generate, 
maintain and monitor a plan, to select and establish specific responses and, therefore, access cognitive 
control (Reiman, Weaver, & Arrington, 2014; Stein, Luppa, Brähler, König, & Riedel-Heller, 2010). 
Compared with the Category Fluency test, which consists of a single restriction (name animals) and is 
of a shorter duration (1 minute), the Letter Fluency test represents a more complex task. Increasing 
task complexity is thought to place higher demands on higher order cognitive abilities (Halford, Baker, 
McCredden, & Bain, 2005) such as cognitive control processes. Accordingly, the Letter Fluency test is 
thought to rely more on cognitive control processes but less on semantic knowledge than the Category 
Fluency task (Delis & Kaplan, 2001). Trial 3 from the Stroop Test (Troyer et al., 2006) requires 
subjects to accurately name the color in which 24 non-congruent color words are printed (i.e. the word 
blue is printed in red color). Accordingly, participants need to maintain a goal while inhibiting a 
routine response in favor of a less familiar one, a process which typically involves cognitive control 
(West et al., 2002). The Five-Point Test (Regard et al., 1982) represents figural fluency and requires 
participants to draw as many different figures as possible within 3 minutes by connecting dots 
displaying the five-dot arrangement on dice. Participants, therefore, need to follow a mental strategy 
and monitor their performance. This coordination of information to select appropriate behavioral 
responses represents aspects of cognitive control (Kelemen & Fenton, 2010).   
The simplest method to compute IIV is to calculate the intraindividual standard deviation (ISD) 
(Nesselroade & Salthouse, 2004) across each individual’s accuracy scores. Before computing ISD, 
two missing Stroop Test raw scores in HCS and MCI were imputed with the expected-maximization 
algorithm in SPSS. Effects associated with age, education and gender, and potential interactions were 
estimated from the HCS’ raw scores by using General Linear Model. Parameters for age, education 
and gender from this model were used to predict accuracy scores in both MCI and AD subjects. 
Standardized residuals for MCI and AD were then calculated by subtracting the predicted from the 
observed accuracy scores and dividing it by the model’s standard error. Residuals from the Stroop Test 
were log-transformed to achieve normal distribution, and multiplied by -1 to adjust for scaling 
difference. In sum, this procedure generated standardized residuals representing adjusted accuracy 
scores with a mean of 0 and variance of ~1 in HCS. By restricting the variance to ~1 in HCS, we 
lowered the risk of overestimating IIV in HCS due to higher mean performance, since ISD is not 
independent from the mean (Allaire & Marsiske, 2005). Accordingly, residuals deviating from 0 
represented adjusted accuracy scores for MCI and AD subjects. We then computed ISD across each 
individual’s residuals on Digit Span Forward, Word List Learning, and Category Fluency representing  
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across-domain IIV, whereas ISD across residuals on Letter Fluency, Stroop Test, and Five-Point Test 
represented within-domain IIV. To further address the association between ISD and mean 
performance, we used the intraindividual mean (IIM) across residuals underlying across-domain IIV 
(across-domain IIM) and across residuals underlying within-domain IIV (within-domain IIM) as 
covariates in all relevant analyses. 
 
Genotyping 
APOE genotyping was performed by restriction isotyping as described previously (Hixson & Vernier, 
1990). For analysis, participants were classified as either carriers (APOE ε2/ε4, ε3/ε4 and ε4/ε4) or 
non-carriers of the APOE ε4 allele. 
 
Statistics 
Group comparisons of normally distributed demographic data, raw and adjusted cognitive data were 
applied using univariate analysis of variance (ANOVA) followed by Sidak post hoc tests correcting 
for multiple comparisons. Kruskal-Wallis tests followed by Mann-Whitney tests corrected for multiple 
comparisons were performed to compare not normally distributed variables. Pearson’s chi-square test 
was used for categorical variables. Univariate analyses of covariance (ANCOVA) with diagnostic 
group treated as the main effect were performed to evaluate group wise differences in across- and 
within-domain IIV. Although influences of age, gender and education had already been taken into 
account while computing IIV, they were used as covariates to control for influences on IIV. Across- 
and within-domain IIM represented additional covariates. Sum of Square Type III was applied to take 
into account the unbalanced design. Significant group effects were further examined using Sidak post 
hoc test correcting for multiple comparisons. For parametric analyses, tests were performed with a 
significance level of p < 0.05. Manually correcting for multiple comparisons, a significance level of p 
< 0.017 (0.05/3 = 0.017) was applied for non-parametric analyses. All analyses were performed as 
two-sided tests by using the statistical analysis software package PASW 19.0 for Windows. 
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5.1.4 Results 
 
Descriptive statistics for demographic information and adjusted cognitive data, as well as cognitive 
raw data is listed in Table 1.  
 
Table 1  Demographic information and cognitive measures per diagnostic group 
Characteristic  HCS  MCI  AD p Value 
      
N  149 31 26 N/A 
Age, y  68.93    5.75 73.39     5.93 77.65     6.10 0.000* a,b,c 
Gender, M/Fd  59/90 11/20 7/19 0.455 
Years of education  14.51    3.25 12.94     2.95 11.12     2.81 0.000* a,b 
MMSEe  29.43    0.82 27.87     1.77 21.46     3.78 0.000* a,b,c 
Digit Span Forward raw   7.49    1.78   5.90     1.33   5.35     1.81 N/A 
  res   0.00    0.99   -0.63     0.71  -0.65     1.16 0.000* a,b 
Word List Learning raw 23.70    2.87  17.13    4.49 12.27     4.01 N/A 
  rese   0.00    0.99   -2.25    1.58  -3.91     1.43 0.000* a,b,c 
Category Fluency raw 23.91    4.74  17.71    5.10 11.08     5.25 N/A 
  res   0.00    0.99   -1.22    1.08  -2.53     1.15 0.000* a,b,c 
Letter Fluency raw 31.65    8.93  22.58  10.21 13.23     5.96 N/A 
  res   0.00    0.99    0.29    1.52  -0.66     1.12 0.004* a,c 
Stroop Trial 3 raw 28.36    8.70  35.29    9.94 69.04    48.33 N/A 
  rese   0.00    0.99   -0.74    1.01  -2.74     2.20 0.000* a,b,c 
Five-Point Test raw 25.96    7.00  18.74    6.70 12.19     5.27 N/A 
  res   0.00    0.99   -0.91    0.87  -1.70     0.78 0.000* a,b,c 
Across-domain IIM    0.00    0.63   -1.37    0.82  -2.36     0.92 0.000* a,b,c 
Within-domain IIM    0.00    0.73   -0.45    0.86  -1.70     0.99 0.000* a,b,c 
Across-domain IIVf    0.91    0.62    0.98    0.58   1.52     0.75 0.001* a,c 
Within-domain IIVf    0.75    0.55    1.01    0.52   1.23     0.65 0.002* a,b 
      
 
Note. HCS = healthy control subjects; MCI = mild cognitive impairment; AD = Alzheimer’s disease; 
N/A = not applicable; MMSE = Mini-Mental State Examination; res = standardized residuals; raw = 
raw scores; IIM = intraindividual mean; IIV = intraindividual variability. Data are means and standard 
deviations unless specified otherwise. Standardized residuals of cognitive test scores for MCI and AD 
were calculated by using parameter estimates for age, education and gender in HCS. * Significant 
global p value test by analysis of variance unless specified otherwise. Post hoc tests indicated 
significant differences at p ≤ 0.05 or lower (parametric tests) and p <0.01 or lower (non-parametric 
tests) for aHCS vs. AD; bHCS vs. MCI; cMCI vs. AD. dPearson’s X2 test. eKruskal-Wallis test followed 
by Mann-Whitney test. fAnalyses of covariance, means adjusted for age, gender, education and across- 
or within-domain IIM.  
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Across-domain IIV was influenced by age (F(1,199) = 3.958; p = .048; η2P = .020), and slightly by 
across-domain IIM (F(1,199) = 3.520; p = .062; η2P = .017) but not by education (F(1,199) = 0.076; p 
= .783; η2P = .000) or gender (F(1,199) = 1.346; p = .247; η2P = .007). But first and foremost we 
observed a main effect between the diagnostic groups (F(2,199) = 7.310; p = .001; η2P = .068). 
Patients with AD revealed higher IIV than HCS (p = 0.002; 95% CI = 0.192 – 1.030) and MCI (p = 
0.001; 95% CI = 0.170 – 0.892), whereas IIV did not differ between MCI and HCS (p = 0.896; 95% 
CI = -0.226 – 0.387) (Figure 1, A). Within-domain IIV was not influenced by age (F(1,199) = 0.054; p 
= .816; η2P = .000), education (F(1,199) = 2.237; p = .136; η2P = .011), gender (F(1,199) = 2.613; p = 
.108; η2P = .013) or within-domain IIM (F(1,199) = 1.500; p = .222; η2P = .007), but differed among 
diagnostic groups (F(2,199) = 6.330; p = .002; η2P = .060). IIV was higher in AD than HCS (p = 
0.004; 95% CI = 0.126 – 0.825). But contrary to across-domain IIV, within-domain IIV was similar in 
AD and MCI (p = 0.374; 95% CI = 0.142 – 0.582). More importantly, there was a strong trend for 
higher IIV in MCI than in HCS (p = 0.055; 95% CI = -0.004 – 0.514) (Figure 1, B).  
 
 
 
 
Figure 1 Comparison of intraindividual variability (IIV) scores between diagnostic groups. 
Intraindividual standard deviation (ISD) representing mean across-domain IIV (A) and mean within-
domain IIV (B) per diagnostic group (HCS = healthy control subjects; MCI = mild cognitive 
impairment; AD = Alzheimer’s disease). Error bars display 95% confidence interval for the mean. 
Pairwise p values shown are based on Sidak Post Hoc tests following analyses of covariance for the 
omparison of means adjusted for age, years of education, gender, as well as mean across-domain 
performance (A) and mean within-domain performance (B) respectively. 
 
 
To evaluate whether there was a relationship between IIV scores, a difference score was calculated by 
subtracting within- from across-domain IIV. ANCOVA was performed by treating age, education, 
gender, and across- and within-domain IIM as covariates. The effect of diagnostic group did not 
approach significance (F(2,198) = 1.497; p = .226; η2P = .015), indicating similar differences between 
IIV scores across diagnostic groups. The qualitative analysis of difference scores, however revealed 
positive difference scores within each group (HCS: M = 0.141, SD = 0.805; MCI: M = 0.005, SD = 
28 
 
0.757, AD: M = 0.340, SD = 0.989), indicating a tendency toward higher across- than within-domain 
IIV in these groups.  
The relationship between APOE status and IIV was explored in a subsample with available genotype. 
Descriptive statistics for demographic information and adjusted cognitive data is listed in Table 2.  
To compare IIV scores between ε4 carriers and non-carriers within each group, we performed 
ANCOVAs by treating gender as a covariate in MCI. Across-domain IIV did not vary with APOE 
status in HCS (F(1,111) = 0.368; p = .545; η2P = .003), MCI (F(1,27) = 0.227; p = .638; η2P = .008) or 
AD (F(1,21) = 0.003; p = .957; η2P = .000). Likewise, within-domain IIV did not vary as a function of 
APOE status in MCI (F(1,27) = 0.348; p = .560; η2P = .013) or AD (F(1,21) = 0.149; p = .703; η2P = 
.007). In HCS, however, there was a weak though significant effect of APOE status (F(1,111) = 3.972; 
p = .049; η2P = .035) indicating increased within-domain IIV in ε4 carriers. 
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5.1.5 Discussion 
 
This study examined whether two different accuracy-based IIV measures on established 
neuropsychological tasks differed between HCS, MCI and AD. Our results suggest an increasing 
breakdown of cognitive control functions early in prodromal AD resulting in increased IIV. More 
precisely, across- and within-domain IIV, as used in the present study, may differ from each other as a 
function of cognitive control required by the underlying tasks. Within-domain IIV tapping cognitive 
control functions more closely was increased in AD and MCI versus HCS, and appears to constitute a 
potential marker for the detection of prodromal AD at the MCI stage. Across-domain IIV tapping less 
cognitive control functions was increased in AD versus MCI and HCS, and may detect incipient dementia 
and separate AD from the MCI stage.  
The establishment of cognitive markers that accurately predict the diagnosis of AD and its preclinical 
manifestation MCI, supports the effort of early detection. Mean performance in tests of verbal episodic 
memory (Derby et al., 2013) and executive function (Schroeter et al., 2012) in particular are known 
markers for predicting AD. The reliable detection of early cognitive impairment based on mean cognitive 
performance in clinical routine, however, poses a challenge. Most importantly, cognitive changes in 
subjects with high educational background may be present prior to a clinical diagnosis but may be very 
subtle, and therefore may be undetected. Cognitive measures that discriminate between MCI due to AD 
and HCS based on abilities relevant to everyday life (i.e. Bird et al., 2010) might further support the 
reliable early detection, but such tests have not been under ample investigation. Across- and within-
domain IIV was found to be independent from the mean cognitive performance, and might therefore 
represent a more sensitive early marker of cognitive impairment than mean cognitive performance.  
Although it represents an easy to use measure in clinical routine (Holtzer et al., 2008) only a few studies 
have investigated IIV across accuracy scores from tests representing different cognitive domains in HCS 
and AD (Brewster et al., 2012; Christensen et al., 1999; Lindenberger & Baltes, 1997; MacDonald et al., 
2012) or in HCS, MCI and AD (Tractenberg & Pietrzak, 2011). Even though IIV has been related to 
impaired cognitive control functions (MacDonald et al., 2009), we are not aware of any study 
investigating IIV across accuracy scores from tests uniquely representing cognitive control in these 
groups. Latency-based IIV has been suggested to be a more sensitive measure than accuracy-based IIV 
(Hultsch et al., 2000), and the direct comparison of our results with work on latency-based IIV is 
challenging. However, different studies have demonstrated a relationship between these measures 
(Hilborn et al., 2009; Hultsch et al., 2002). Accordingly, increased latency- and accuracy-based IIV have 
been linked to older age (Hilborn et al., 2009; Hultsch et al., 2002; Lövden et al., 2007; West et al., 2002), 
cognitive decline (Kliegel & Sliwinski, 2004; Lövden et al., 2007), and to predict probable AD (Brewster 
et al., 2012) and incident dementia (Holtzer et al., 2008). IIV has therefore widely been accepted as a 
stable trait (MacDonald, Nyberg, & Backman, 2006) - possibly reflecting central nervous system integrity 
(MacDonald et al., 2009). More precisely, evidence for a strong association between IIV and frontal gray 
and white matter integrity (Lövdén et al., 2013; Stuss, Murphy, Binns, & Alexander, 2003), and evidence 
of changed gray and white matter integrity in MCI and AD (Jackson et al., 2012; Radanovic et al., 2013; 
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Yang et al., 2012) support the idea of frontal system disruptions underlying increased IIV in dementia 
(Jackson et al., 2012).  
It is beyond the aim of our study to draw direct inferences about the origins of IIV. However, consistent 
with our hypothesis and the literature (MacDonald et al., 2012; Tractenberg & Pietrzak, 2011), we found 
increased across-domain IIV in AD versus HCS and in AD versus MCI. Therefore, across-domain IIV 
was similar in MCI and HCS. Even though others have examined latency-based IIV within but not 
accuracy-based IIV across non-cognitive control tasks (Tales et al., 2012), they have also reported similar 
IIV in these groups. Moreover, MCI subjects who later converted to dementia were found to have higher 
IIV than non-converters. The absence of a group difference between MCI and HCS in our study may 
therefore be related to a low proportion of future converters in our MCI group. Additionally, and since 
higher IIV has been found in tasks requiring cognitive control (MacDonald et al., 2009), the requirement 
of cognitive control processes in the tasks underlying across-domain IIV might have been too limited to 
differentiate between these groups. Consistent with this assumption, and consistent with the literature on 
latency-based within-domain IIV (Duchek et al., 2009) we found within-domain IIV, and hence IIV 
across tasks placing more demands on cognitive control processes, being increased in MCI versus HCS. 
Considering impaired cognitive control functions in MCI and AD (Schroeter et al., 2012), one might have 
expected increased within-domain IIV in AD versus MCI. Against our expectations it was similar in both 
groups. Since the use of a high number of trials has previously been proposed to reliably detect IIV 
(Schmiedek, Lövdén, & Lindenberger, 2009), it might be less pronounced when computed across three 
accuracy scores only, even when computed across cognitively demanding tasks as in our study. 
The similar difference scores in all groups offer additional support for increasing accuracy-based IIV 
across groups in general. Though not significantly different from the difference scores in HCS and AD, it 
was very small in MCI (M=0.005), reflecting the increase in within-domain IIV/stability in across-domain 
IIV between HCS and MCI. Due to the dependence of IIV on cognitive control tasks, higher within- than 
across-domain IIV may be expected. However, the higher across-domain IIV might be caused by the 
early deterioration of episodic memory (Albert et al., 2011) and short-term memory capacity (Schmitt et 
al., 2009) compared to other cognitive domains in the disease process. Consequently, and although mean 
performance was considered in the relevant analyses, the use of a verbal learning task and a task assessing 
short-term memory capacity might have triggered higher across-domain IIV. 
Additionally, we found increased within-domain IIV in HCS ε4 carriers versus non-carriers, whereas 
there was no ε4-related change in IIV in the other groups. Our result is consistent with findings from 
Duchek et al. (2009) who have reported increased latency-based IIV in a cognitive control task, but 
similar IIV in tasks without cognitive control components in HCS ε4 carrier vs. non-carrier. Since the 
frontal lobe constitutes a brain region that manifests ε4-effects even early in the disease (Filbey et al., 
2010), and is thought to be at the basis of IIV (MacDonald et al., 2009), the present findings offer further 
support for a relationship between within-domain IIV and APOE status. It may, however, well be that ε4-
related change in IIV appears in HCS but may not be evident by the MCI and AD stage. 
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The major limitation of our study is related to the selection of the tasks. The limited number of available 
neuropsychological tests did not allow applying factor analyses. Hence, the tasks and their domain-
relatedness were identified following the literature. Based on the high engagement of cognitive control 
processes, we identified executive function tasks to calculate within-domain IIV. However, cognitive 
control processes affect a wide range of cognitive functions. This is why we aimed to identify tasks 
placing low demands on cognitive control for across-domain IIV, and tasks placing high demands on 
cognitive control for within-domain IIV. This approach, however, revealed potential confounding factors 
which make it difficult to clearly determine whether our results can be attributed to the fact that IIV was 
calculated across versus within-domain, or to the fact that the underlying tasks elicited low versus high 
cognitive control. However, a higher number as well as a wider range of neuropsychological tests would 
be required to clearly differentiate between these aspects. Hence, only cautious conclusions can be drawn 
based on our results. Both aspects might be considered relevant with regard to across-domain IIV. More 
precisely, similar across-domain IIV between HCS and MCI is most likely based on equally reduced 
cognitive abilities across domains in MCI (see Table 1). Although cognitive control processes are 
expected to be impaired in prodromal AD, the low level of cognitive control processes elicited by these 
tasks may have been responsible for the uniformity of the decrease. The impairment of cognitive control 
processes, however, may have been sufficient to produce variation across tasks in AD (e.g. unequally 
decreased test performances in AD vs. MCI, see Table 1). In contrast, the aspect of high versus low 
cognitive control might be considered relevant with regard to within-domain IIV. Increased within-
domain IIV in MCI is most likely based on unequally decreased performances in within-domain IIV tasks 
(see Table 1). If it was the across versus within-domain aspect that was critical, equally decreased 
performances could have been expected. Impaired cognitive control processes producing inconsistencies 
across performances in cognitive control sensitive tasks, and hence, producing higher within-domain IIV 
in MCI seem more plausible. The further reduction of cognitive control abilities in AD might lead to two 
different scenarios: a) further increased within-domain IIV due to inconsistent test performances or b) 
reduced within-domain IIV based on floor effects. Since tasks with potential floor effects were excluded, 
the latter does rather not apply. Although within-domain IIV did not differ significantly between MCI and 
AD, IIV was higher in AD (Figure 1), indicating further increasing IIV. The lack of a significant 
difference might indeed have been caused by the low sample size, and by the very subtle characteristic of 
within-domain IIV in general. The finding of higher across- than within-domain IIV across the groups in 
turn is most likely related to inconsistent performances across tests representing different cognitive 
domains. In summary, and although the present results must be interpreted with caution, our results 
indicate that the aspect of across versus within domain might be most relevant for the general 
characteristic of the IIV scores (higher across- than within-domain IIV). In contrast, the aspect of high 
versus low cognitive control might be at the basis of within-domain IIV group differences. 
The minor limitations of our study are attributed to the cross-sectional design. Our results, therefore, do 
not permit to claim causality regarding the relationship between AD pathology and IIV. More precisely, it 
has been argued that cross-sectional data do not permit to clearly distinguish variability caused by aging 
or neurodegeneration from stable individual characteristics (Lindenberger & Potter, 1998). This risk was 
addressed by treating age and within- and across-domain IIM as covariates in all analyses. Furthermore, 
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most test performances underlying IIV were also used for diagnostic purpose, thus posing the risk of 
circularity. However, we assume the risk to be minimal, since the outcome of interest in the present study 
was the ISD calculated across tasks. In addition to that, neuropsychological tasks that had not been used 
for IIV calculation, wide-ranging medical information, and clinical evaluation also contributed to the 
diagnosis. Another limitation is related to the multidimensional nature of the neuropsychological tasks. 
Although the tasks which were used to calculate within-domain IIV place high demands on cognitive 
control processes, they do not exclusively assess this particular cognitive function.  Processing speed 
(Greenaway, Smith, Tangalos, Geda, & Ivnik, 2009), inhibition (Troyer et al., 2006) and visuo-
construction (Lezak et al., 2004) represent further cognitive abilities that are crucial for successfully 
performing the Letter Fluency task, the Stroop Test and the Five-Point Test, respectively. They might, 
therefore, represent potential confounders in the present study. Since the tasks which were used to 
calculate across-domain IIV, however, place fewer demands on cognitive control processes than the task 
which were used to calculate within-domain IIV, we assume this risk to be reduced. 
Despite these limitations, and although comparison with other studies may be limited due to 
methodological differences among studies (e.g. IIV definition and measures, diagnostic criteria), the 
present study offers further support for increased IIV in MCI and AD in general, and for increased 
accuracy-based IIV in particular. From a clinical point of view, accuracy-based IIV may be more useful 
than latency-based IIV measures in everyday clinical routine. First, tasks assessing cognitive control 
functions and non-cognitive control functions are usually included in standard clinical 
neuropsychological test batteries, and therefore allow IIV calculations without applying additional tests. 
Second, assessing accuracy-based IIV avoids the necessity to add multiple trials or blocks of the same 
task to the standard test battery, and therefore reduces the burden for the patients in dementia diagnostics. 
The present study, therefore, underscores the importance of considering the value of IIV in the early 
detection of prodromal AD and demonstrates the usability of accuracy-based IIV measures in AD 
diagnosis. Both across- and within-domain IIV may represent potential cognitive markers for the early 
detection of prodromal AD. However, further examination by using a higher number of more complex 
tests in a longitudinal design is needed to provide more specific information about the predictive value of 
these IIV scores. 
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5.2 Study 2: Intraindividual variability and gray matter volumes in future 
Alzheimer’s disease patients 
 
Intraindividual variability across cognitive tasks is not increased and not related to gray matter 
volumes in Alzheimer’s disease patients at predementia stage 
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5.2.1 Abstract 
 
Potential treatments for Alzheimer’s disease (AD) may be most effective in prodromal stages, referred to 
as mild cognitive impairment (MCI). However, there is heterogeneity among MCI, with only some 
patients progressing to AD. Thus, the establishment of biomarkers that identify future converter to AD is 
crucial. Previous results from our group have indicated that cognitive intraindividual variability (IIV) 
across accuracy scores from cognitive control tasks (within-domain IIV) might represent an early marker 
for AD. Furthermore, although IIV across reaction time tasks has been associated with prefrontal and 
parietal gray matter volumes, neuronal correlates of IIV across accuracy score, and hence, of within-
domain IIV are unknown. With the present study, we aimed to further investigate the potential value of 
within-domain IIV acting as early marker for AD, and to examine its relationship with gray matter 
volumes. For this purpose, we examined the correlation between within-domain IIV and volumes of IIV-
relevant brain regions such as dorsolateral- and ventrolateral prefrontal (dlPFC, vlPFC) as well as 
posterior parietal cortices (PPC) in patients with stable MCI (MCI-S, n=18), future converter at baseline 
(MCI-CB, n=10) and healthy control subjects (HCS), and the ability of within-domain IIV to predict 
diagnostic group membership. However, within-domain IIV was similar in MCI-S and HCS, and more 
importantly in MCI-CB and HCS, preventing us from performing logistic regression analyses. 
Furthermore, we did not observe significant relationships between within-domain IIV and gray matter 
volumes in either of the groups. Our results, therefore, not only contradict the assumption of prefrontal 
and parietal gray matter volumes being related to within-domain IIV in MCI but limit the potential of 
within-domain IIV as early marker for AD. However, the low characterization of within-domain IIV in 
rather small samples may have essentially influenced the present results. We propose further studies with 
larger cohorts to further examine within-domain IIV as a predictor for AD, and studies including AD 
patients to examine the relationship between within-domain IIV and gray matter volumes. 
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5.2.2 Introduction 
 
Evidence for treatment methods being most efficacious in preclinical or early disease stages (Golde et al., 
2011; Sperling, Jack, et al., 2011) has increased the importance of reliable methods for the early detection 
of Alzheimer’s disease (AD) and its preclinical manifestations, referred to as mild cognitive impairment 
(MCI). Although MCI subjects of the amnestic subtype (aMCI) are more likely to progress to AD than 
subjects of the non-amnestic subtype (Roberts et al., 2014), there is heterogeneity even among aMCI. 
Some patients develop different forms of dementia than AD, whereas others remain stable for a long time, 
and still others may even reveal normal cognitive abilities again (Roberts et al., 2014). The establishment 
of markers that accurately identify future converter to AD is therefore crucial. 
Cognitive intraindividual variability (IIV) has evidenced representing a potential marker of early 
cognitive impairment (MacDonald et al., 2009), with IIV across multiple trials of a reaction time (RT) 
task or across different RT tasks (latency-based IIV) predicting mild cognitive impairment (Bielak, 
Hultsch, Strauss, MacDonald, & Hunter, 2010; Cherbuin, Sachdev, & Anstey, 2010), and being increased 
in MCI (Christensen et al., 2005; Dixon et al., 2007; Duchek et al., 2009; McLaughlin et al., 2010; 
Strauss et al., 2007) and AD (Hultsch et al., 2000; Jackson et al., 2012; Rochat et al., 2013). However, 
integrating repetitive RT tasks into already existing comprehensive test batteries may increase the testing-
associated burden on patients. Although IIV across accuracy scores of different cognitive tasks (accuracy-
based IIV) may provide an uncomplicated alternative, it has not been investigated extensively. 
Nonetheless, the use of accuracy-based IIV across tests representing different cognitive domains (across-
domain IIV) has been promising  for predicting global (Kliegel & Sliwinski, 2004) and functional decline 
(Morgan et al., 2012), incident dementia (Holtzer et al., 2008) and probable AD (Vaughan et al., 2013). 
Likewise, it was found to be increased in MCI and AD (Kälin et al., 2014; MacDonald et al., 2012; 
Tractenberg & Pietrzak, 2011). IIV has been proposed to index cognitive control processes (MacDonald 
et al., 2009). Results from our previous study investigating accuracy-based IIV across tests placing high 
demands on cognitive control processes (within-domain IIV) have supported the idea of a breakdown of 
cognitive control functions leading to increased within-domain IIV in MCI and AD when compared with 
healthy control subjects (HCS) (Kälin et al., 2014). Thus, increased within-domain IIV may represent an 
early marker for AD. With the present study, we aimed to further verify the potential value of within-
domain IIV as early marker for AD, and to obtain further information about neuronal correlates of within-
domain IIV.  
Despite the growing number of IIV studies, little is known about its structural brain correlates. Cognitive 
control processes, and hence IIV are thought to be supported by the frontal cortex (MacDonald et al., 
2009) in general, and by dorsolateral and ventrolateral prefrontal cortices (dlPFC; vlPFC) in particular 
(Casey, Nigg, & Durston, 2007; Levy & Wagner, 2011; Liston et al., 2006; Miller & Cohen, 2001; 
Weissman et al., 2006). Other regions outside of the frontal lobe that have been associated with cognitive 
control processes include parietal cortex regions (Wilk et al., 2012). Correspondingly, in agreement with  
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studies associating white matter integrity with reaction time performance (Bender & Raz, 2012; Madden 
et al., 2004), different studies have evidenced an association between latency-based IIV and white matter 
alterations in temporal (Ullen, Forsman, Blom, Karabanov, & Madison, 2008), parietal (Bellgrove, 
Hester, & Garavan, 2004; Jackson et al., 2012; MacDonald, Nyberg, Sandblom, Fischer, & Bäckman, 
2008; Ullen et al., 2008; Wilk et al., 2012) and frontal regions in general (Bunce et al., 2007; Lövdén et 
al., 2013), and prefrontal cortex (Ullen et al., 2008), dlPFC and vlPFC (Jackson et al., 2012) in older age 
in particular. Although findings of higher latency-based IIV in subjects with frontal lobe dementia 
(Murtha, Cismaru, Waechter, & Chertkow, 2002) and in subjects with dlPFC lesions (Stuss et al., 2003) 
have indicated a link between gray matter alterations and increased latency-based IIV as well, different 
studies have failed to observe such a relationship (Lövdén et al., 2013; Moy et al., 2011; Ullen et al., 
2008; Walhovd & Fjell, 2007). Less is known about structural correlates of accuracy-based IIV. Only 
Lövdén et al. (2013) have examined the relationship between accuracy-based IIV and white as well as 
gray matter volumes in cognitively normal subjects. The authors have reported a relationship between 
dlPFC gray matter volume and IIV, but not between frontal white matter and IIV, therefore providing 
support for a potential relationship between accuracy-based IIV and gray matter volumes in IIV-relevant 
regions.  
Given the increasing support for higher IIV in MCI (e.g. McLaughlin et al., 2010) and AD (e.g. Kälin et 
al., 2014), it is surprising that only a few studies have investigated structural correlates of IIV in AD. So 
far, relationships have only been reported between latency-based IIV and white matter volumes in dlPFC, 
vlPFC, superior frontal gyrus and corpus callosum in MCI and mild AD (Anstey et al., 2007; Jackson et 
al., 2012). However, and to our knowledge, there has been no study investigating the relationship between 
accuracy-based IIV and gray matter alterations in MCI. Cortical brain atrophy due to early involvement 
of neurofibrillary tangle formation followed by neuronal loss has repeatedly been related to increasing 
cognitive impairment in MCI and AD (e.g. Carter et al., 2014). Apart from memory impairment (Bollo-
Gasol, Pinol-Ripoll, Cejudo-Bolivar, Llorente-Vizcaino, & Peraita-Adrados, 2014), executive dysfunction 
in general (e.g. da Costa Armentano et al., 2013), and reduced cognitive control processes (Rapp & 
Reischies, 2005; Schroeter et al., 2012) in particular represent early clinical signs of the disease. A 
relationship between prefrontal cortex volumes and within-domain IIV is therefore highly likely. 
Accordingly, we aimed to investigate the relationship between within-domain IIV and regional gray 
matter volumes. We correlated within-domain IIV and volumes of IIV-relevant brain regions in aMCI 
who remained cognitively stable (MCI-S), aMCI with future worsening of cognitive functions and 
conversion to AD (MCI-CB) and HCS to gain more information about neuronal correlates of within-
domain IIV in AD pathology. We furthermore aimed to obtain more information about within-domain 
IIV acting as potential early marker for AD. To this end, we explored the contribution of within-domain 
IIV to predict membership to diagnostic groups. We hypothesized a negative relationship between within-
domain IIV and gray matter volumes of IIV-relevant brain regions in MCI-CB but not MCI-S, and 
within-domain IIV contributing to the prediction of MCI-CB but not MCI-S membership.   
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5.2.3 Methods 
 
Participants 
We selected participants from pre-existing longitudinal cohorts at the Memory Clinic of the Division of 
Psychiatry Research and Psychogeriatric Medicine, University of Zurich. MCI was diagnosed according 
to Winblad et al. (2004) after a comprehensive clinical and neuropsychological work-up. Conversion to 
dementia was diagnosed when subjects met National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-
ADRDA) (McKhann et al., 1984) criteria for probable AD. All diagnoses were made by a 
multidisciplinary team under the supervision of an experienced psychiatrist.  
For the present study, inclusion criteria for MCI subjects were: diagnosis of aMCI and availability of 
magnetic resonance imaging (MRI) as well as cognitive data at baseline. Exclusion criteria were: MR 
exclusion criteria, left-handedness, evidence for the use of psychoactive medication, abuse of alcohol and 
drugs, other past or present psychiatric or neurological diseases or significant other systemic diseases, or 
MRI findings of infarction or other focal lesions, multiple lacunes or lacunes in critical memory 
structures. A total of 46 baselines from subjects with aMCI were considered for the present study.  From 
this sample, 8 subjects were excluded from the analyses due to left-handedness (n=5), structural 
abnormalities in the brain (n=1), and T1 parameters that were inconsistent with the MRI study protocol 
(n=2). Due to a change in test batteries, 10 MCI subjects were missing a cognitive test score relevant for 
computing IIV, and were excluded from the analyses. The remaining population at baseline was then 
stratified into two subgroups according to longitudinal clinical information; subjects who remained 
cognitively stable during an approximately 2-year follow-up (MCI-S, n=18), and subjects with future 
worsening of cognitive impairment and conversion to probable AD within the 2-year follow-up (MCI-
CB, n=10). Inclusion criteria for HCS were: stable cognitive health ascertained by clinical work up and 
neuropsychological testing during a roughly 2-year follow-up, age between 59 and 87. Exclusion criteria 
were: MRI exclusion criteria, left-handedness, evidence for abuse of alcohol and drugs, psychiatric or 
neurological diseases or significant other system diseases. HCS were identified for group wise age and 
gender matching with MCI-S and MCI-CB, respectively. The neuropsychological test battery consisted of 
multiple tests covering the following cognitive domains: episodic memory, executive function, 
attention/psychomotor speed, language and visual-constructive abilities. Impairment was defined if at 
least one score per domain was 1.5 standard deviations (SD) below group means provided by test-specific 
normative data.  
Accordingly, a total of 18 MCI-S and 10 MCI-CB, as well as age and gender matched HCS were 
considered for the current analysis. The final demographic details are presented in Table 3. This study 
was approved by the cantonal ethics committee of canton Zurich, Switzerland, in accordance with the 
Helsinki Declaration. All participants provided written informed consent prior to study inclusion. 
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Computation of intraindividual variability 
For calculating within-domain IIV, we used accuracy scores from three tests, each representing executive 
functions and eliciting recruitment of cognitive control processes. The rationale behind the selection of 
the tasks has been described in detail elsewhere (Kälin et al., 2014). Briefly, we identified tasks with less 
than 1% missing values, and with no ceiling or floor effects to prevent suppressing variation at the 
extreme ends of the distribution. Therefore, we used accuracy scores from the Letter Fluency test (letter 
S), Trial 3 from the Stroop Test (Troyer et al., 2006) and the Five-Point Test (Regard et al., 1982).  
The simplest method to compute IIV is to calculate the intraindividual standard deviation (ISD) 
(Nesselroade & Salthouse, 2004) across each individual’s accuracy scores. Before computing ISD, one 
missing Stroop Test score in HCS and one missing Letter Fluency test score in MCI were imputed with 
the expected-maximization algorithm in SPSS. Then, the accuracy scores were z-transformed based on 
the mean and standard deviation of the pooled sample (MCI-S, MCI-CB, and HCS). The z-scores from 
the Stroop Test were multiplied by -1 to adjust for scaling difference. We then computed ISD across each 
individual’s z-transformed accuracy scores on Letter Fluency, Stroop Test, and Five-Point Test 
representing within-domain IIV. To address the association between ISD and mean performance (Allaire 
& Marsiske, 2005), we used the intraindividual mean (IIM) across z-transformed accuracy scores from 
tests underlying within-domain IIV (within-domain IIM) as covariate in all relevant analyses. 
 
Magnetic resonance image acquisition and processing 
All subjects were scanned on the same 1.5 Tesla Phillips Achieva scanner using an 8-element head coil. 
Whole-brain high-resolution three-dimensional (3D) T1-weighted structural data was obtained by using 
the following scanning parameters: 166 slices, repetition time: 6.9 milliseconds, echo time: 3.2 
milliseconds, flip angle: 8°, field of view: 240 x 240 x 166 millimeters (anterior-posterior, foot-head, 
right-left), slice thickness: 1 millimeter, total scan time: 15 min.  
All volume measures were estimated by using the fully automated CIVET pipeline (version 1.1.10; 
Montreal Neurological Institute McGill University, Montreal, Quebec, Canada) (Ad-Dab'bagh et al., 
2006). Briefly, magnetic resonance images of each subject were first linearly registered to the standard 
stereotaxic ICBM152 template (Collins, Neelin, Peters, & Evans, 1994; Mazziotta et al., 2001). Images 
were corrected for intensity nonuniformity resulting from inhomogeneity in the magnetic field (Sled, 
Zijdenbos, & Evans, 1998). Skulls were stripped from the brain tissue (Smith, 2002), and segmentation 
into white matter, grey matter, and cerebrospinal fluid (CSF) was achieved using the Intensity- 
Normalized Stereotaxic Environment for Classification of Tissues (INSECT) algorithm (Tohka, 
Zijdenbos, & Evans, 2004; Zijdenbos, Forghani, & Evans, 1998). Regional gray matter volume measures 
along the cortical surface were then estimated using the intersection of the gray matter classification 
provided by CIVET and the LONI Probabilistic Brain Atlas (LPBA40) (Shattuck et al., 2008) in MNI 
space. These delineations were then transformed back into native space by using an inverse linear 
transformation (ANIMAL) (Collins, Holmes, Peters, & Evans, 1995) resulting in volumes of 40 cortical 
regions per hemisphere. Furthermore, total incranial volume (eTIV) was estimated following a previously 
validated procedure (Buckner et al., 2004).  
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Volumes of interest in both hemispheres were achieved by combining regional volumes obtained from the 
CIVET pipeline. Dorsolateral prefrontal cortex volumes were acquired by combining volumes of the 
middle and superior frontal gyrus. These regions largely cover Brodmann Areas (BA) 8, BA9 and BA46, 
areas that have previously been used for dlPFC definition (Burgmans et al., 2009; Clerx et al., 2013; 
Echavarri et al., 2011; Tisserand et al., 2002). Ventrolateral prefrontal cortex volumes were obtained 
using inferior frontal gyrus volumes approximately covering BA44, BA45 and BA47 (Badre & Wagner, 
2007; Levy & Wagner, 2011). Posterior parietal cortex volumes included volumes of supramarginal and 
angular gyrus as well as precuneus, covering BA7, BA39 and BA40 (Francois-Brosseau et al., 2009; 
Vingerhoets, 2014). Since previous studies have reported no relationship between accuracy- and latency-
based IIV and gray or white matter volumes in occipital regions (Bunce et al., 2007; Lövdén et al., 2013), 
the occipital lobe was selected as control region. Its volume was acquired by summarizing superior, 
middle and inferior occipital gyrus, cuneus and lingual gyrus volumes (Shattuck et al., 2008).  
 
Statistical analyses 
Group comparisons (MCI-S versus HCS; MCI-CB versus HCS) of normally distributed demographic data 
and cognitive raw scores were applied using analysis of variance (ANOVA). Mann-Whitney U tests were 
performed to compare variables without a normal distribution. Pearson’s chi-square test was used for 
categorical variables. The relationship between raw gray matter volumes and within-domain IIV was 
explored by performing Pearson’s correlation across diagnoses within each group (Group 1: MCI-S and 
HCS; Group 2: MCI-CB and HCS), and by controlling for influences of age, gender, and within-domain 
IIM. Subsequent group comparisons (MCI-S versus HCS; MCI-CB versus HCS) of raw volumes were 
investigated by applying ANOVA, whereas differences in within-domain IIV were performed using 
univariate analyses of covariance (ANCOVA) with diagnostic group treated as the main effect and 
within-domain IIM as a covariate. The planned logistic regression analysis to test the ability of within-
domain IIV to predict diagnostic group membership was not performed due to the lack of significant 
group difference. All volume analyses were repeated by using volumes relative to eTIV (volume / eTIV * 
100) in order to adjust volumes for individual differences in head size. Tests were performed with a 
significance level of p < 0.05. Statistical analyses were performed by using the statistical analysis 
software package IBM SPSS statistics 21 for windows. 
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5.2.4 Results 
 
A segmentation map of the summarized regions of interest for volumetric analyses is shown in Figure 2. 
Descriptive statistics for demographic information, cognitive raw scores as well as raw volumes and 
volumes relative to eTIV is listed in Table 3. Compared to HCS, neither of the patient groups differed on 
mean age, years of education or gender. Both patient groups demonstrated significantly lower MMSE 
scores than their HCS matches (Group 1 U=69.00, p=.001; Group 2 U=21.00, p=.025). 
 
 
 
 
Figure 2  Regions of interest that were automatically segmented, namely: ventral lateral prefrontal cortex 
(pink), dorsolateral prefrontal cortex (blue); posterior parietal cortex (green) in a healthy control subject 
(male, 69 years of age). 
 
 
Primary analyses 
The correlation coefficients representing the association between gray matter volumes relative to eTIV 
and within-domain IIV across diagnosis within each group are presented in Table 4. Confirming our 
assumption, within-domain IIV was not significantly correlated with any of the volumes of IIV-relevant 
regions in Group 1. Contrary to our expectation, the same was true for Group 2, where none of the 
correlations were significant as well. Correlation analyses were repeated across all groups (MCI-S, MCI-
CB, and HCS). Again, analyses revealed no significant correlations (data now shown). Correlation 
coefficients were similar when statistical analyses were performed by using raw volumes instead of 
volumes relative to eTIV (Table 4).  
Before logistic regression analysis was performed to investigate the ability of within-domain IIV 
predicting diagnostic group membership, we performed group-wise comparisons. These results together 
with raw scores of cognitive tests are presented in Table 3. Confirming our assumption, within-domain 
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IIV was similar in MCI-S compared to HCS. Against our expectation, however, the same was true for the 
comparison of within-domain IIV between MCI-CB and HCS. The analyses were repeated by pooling 
MCI subjects (MCI-S and MCI-CB versus HCS). However, within-domain IIV was still similar in pooled 
MCI and HCS (data not shown). Based on these result, we refrained from performing the planned logistic 
regression analysis. 
However, and compared to HCS, MCI-S performed significantly worse in the Letter Fluency test 
(F(1,34)=4.85, p=.035) and Stroop Trial 3 (F(1,27=6.54, p=.016) but equal in the Five-Point test. 
Accordingly, within-domain IIM was significantly lower in MCI-S compared to HCS (F(1,27=10.72, 
p=.003). Similarly, MCI-CB performed significantly worse in Stroop Trial 3 compared to HCS 
(F(1,27=6.54, p=.037). Additionally, they performed significantly lower in the Five-Point test (U=19.5, 
p=.019) but equally in the Letter Fluency test when compared with HCS. There was only a tendency 
towards reduced within-domain IIM in MCI-CB (F(1,12)=4.63, p=.05).  
 
Secondary analyses 
Based on absent significant relationships between within-domain IIV and gray matter volumes, we 
performed group wise comparisons of dlPFC, vlPFC and PPC volumes. Results of the comparison of 
volumes relative to eTIV between groups (MCI-S versus HCS; MCI-CB versus HCS) together with raw 
volumes of bilateral structures are shown in Table 3. There were no volumetric differences in any of the 
examined IIV-relevant regions or in eTIV in MCI-S when compared with HCS. Against our expectation, 
though, volume sizes of IIV-relevant regions and eTIV did not differ between MCI-CB and HCS as well. 
Again, analyses were repeated by comparing volumes between pooled MCI groups and HCS. All 
volumes, however, were similar in MCI and HCS (data not shown). Significance and p-values were 
similar when statistical analyses were performed by using raw volumes instead of volumes relative to 
eTIV (Table 3).  
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Table 4  No correlation between gray matter volumes and within-domain IIV 
 
 
Note. HCS = healthy control subjects; MCI-S = stable mild cognitive impairment at baseline; MCI-CB = 
mild cognitive impairment converter at baseline; IIV = intraindividual variability; dlPFC = dorsolateral 
prefrontal cortex; vlPFC = ventral lateral prefrontal cortex; PPC = posterior parietal cortex. Values 
represent correlation coefficients. Volumes were correlated with within-domain IIV by applying 
Pearson’s correlation in pooled groups by controlling for age, gender, and within-domain intraindividual 
mean.  
 
 
  
 Group 1 (HCS=18; MCI-S=18) 
Group 2 
(HCS=10; MCI-CB=10) 
 Within-domain IIV Within-domain IIV 
   
Gray matter volumes mm3   
  dlPFC, right   .155   .135 
  dlPFC, left   .090   .177 
  vlPFC, right   .290   .120 
  vlPFC, left   .216 - .022 
  PPC, right   .164 - .122 
  PPC, left   .171   .042 
  Occipital lobe, right - .082   .385 
  Occipital lobe, left - .013   .163 
 
Gray matter volumes (volume/eTIV*100) 
  dlPFC, right   .151 - .028 
  dlPFC, left   .090   .047 
  vlPFC, right   .308 - .035 
  vlPFC, left   .258 - .239 
  PPC, right   .091 - .378 
  PPC, left   .060 - .076 
  Occipital lobe, right - .018   .371 
  Occipital lobe, left - .165   .067 
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5.2.5 Discussion 
 
With the present study, we aimed to obtain more information about neural correlates of within-domain 
IIV and of its potential as early marker for AD. However, we found no significant relationship between 
within-domain IIV and gray matter volumes in any of the brain regions relevant for IIV (dlPFC, vlPFC, 
PPC) in MCI-S and HCS, or in MCI-CB and HCS. Additionally, within-domain IIV was found to be 
similar not only in MCI-S and HCS but also in MCI-CB and HCS.  
The present result of similar within-domain IIV in MCI-CB and HCS are in contrast with results from our 
previous study where within-domain IIV was increased in MCI compared to HCS (Kälin et al., 2014). 
The lack of a significant difference between MCI-CB and HCS in the present study may, therefore, 
indicate that increased within-domain IIV is not a general characteristic of MCI due to AD but of 
cognitive impairment per se. The subsequently performed comparison of within-domain IIV between 
pooled MCI patients and HCS, however, again showed no significant difference. Another possible 
explanation for contradicting results may be the variation of the sample between the two studies. The 
previous study comprised MCI subjects of both, the aMCI and non-amnestic subtype (nMCI), whereas 
only aMCI subjects were included in the present study. It could be argued that the presumably lower 
range of cognitive impairments in current MCI groups has limited the range of IIV in the present study, 
particularly when considering the within-domain aspect of IIV. More precisely, and assuming impaired 
memory but unimpaired executive functions in aMCI, IIV across tasks representing executive functions 
may be lower in these subjects. This however renders unlikely considering the fact that 89% of aMCI in 
the present study showed impairments in multiple cognitive domains, and taking into account the rather 
low percentage of nMCI in our previous study (13%). We assume it more likely that the absent increase 
of within-domain IIV in MCI-CB is related to the small sample size on the one hand, and to the low 
characteristic utility of accuracy-based IIV on the other hand.  
More precisely, although there has been no other study investigating accuracy-based IIV similar to our 
within-domain IIV, increased accuracy-based IIV has been observed in MCI compared to HCS in a study 
from Tractenberg and Pietrzak (2011). Others, however, have failed to observe increased accuracy-based 
IIV in MCI (Ramratan et al., 2012). Interestingly, and although accuracy-based IIV has failed to predict 
MCI by in a study from Vaughan et al. (2013), it has successfully predicted probable AD in the same 
study. These results fit into the row of other studies reporting increased accuracy-based IIV predicting 
incident dementia (Holtzer et al., 2008) and being higher in AD than in HCS (Kälin et al., 2014). At the 
same time, these results indicate that in MCI, accuracy-based IIV in general might be of low 
characteristic. Although a relationship between accuracy- and latency-based IIV has been reported 
(Hilborn et al., 2009; Hultsch et al., 2002), latency-based IIV has previously been reported a more 
sensitive measure than accuracy-based IIV (Hultsch et al., 2000). Supporting the higher sensitivity of 
latency-based IIV, Ramratan et al. (2012) have found higher latency- but not accuracy-based IIV in MCI. 
If the rather small difference of within-domain IIV between MCI (n=31) and HCS (n=149) (p=.05) in the 
previous study is additionally taken into consideration, it seems likely that the occurrence of a significant 
effect in those groups is highly dependent from the sample size. Hence, it seems as if much larger sample 
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sizes are required to observe a stable effect. In sum, it seems most likely that the lack of a difference of 
within-domain IIV between MCI-CB and HCS is related to the low characteristic utility of accuracy-
based IIV in combination with rather low sample sizes.  
The lack of a significant relationship between within-domain IIV and volumes of IIV-relevant regions 
such as the dlPFC, vlPFC and PPC in turn is most likely related to the low characteristic of both within-
domain IIV and gray matter atrophy in these regions of interest. Neurofibrillary tangle formation in these 
regions occurs at rather late histopathological disease stages (Braak & Braak, 1990). Subjects at such 
early stages as MCI-CB may, therefore, still be free of pronounced frontal and parietal gray matter 
shrinking. Correspondingly, gray matter volumes of dlPFC, vlPFC and PPC were not only similar in 
MCI-S and HCS, but also in MCI-CB and HCS. Nevertheless, results from studies investigating gray 
matter atrophy in MCI have reported inconsistent results. Some studies have indeed observed reduced 
volumes of prefrontal (Han et al., 2012; Mosconi, Andrews, & Matthews, 2013; Zhao et al., 2014) and 
parietal cortex regions (Clerx et al., 2013; Zhao et al., 2014) in MCI, as well as reduced vlPFC (Bell-
McGinty et al., 2005) and prefrontal cortex volumes (Burgmans et al., 2009) in MCI who later converted 
to dementia when compared to non-converter. Others, however, have failed to observe volume 
differences in parietal regions in MCI compared to HCS (Zhang et al., 2013), or in dlPFC when 
comparing future converter to non-converter (Burgmans et al., 2009). These inconsistencies are most 
likely related to sample variations, differences in the definition of the sample (MCI, converter and non-
converter) and hence, in different disease stages of the included subjects.  
Regardless of whether early atrophy in prefrontal or parietal cortex regions is existent or not, the present 
results do not support our assumption of within-domain IIV being related to the investigated gray matter 
volumes. To our knowledge, there has been no other study investigating this relationship in MCI or AD. 
By using different measurements of IIV, other studies have indeed observed a relationship between IIV 
and gray matter volumes of prefrontal cortex regions. Specifically, one study has reported a significant 
relationship between dlPFC gray matter volume and accuracy-based IIV in HCS (Lövdén et al., 2013), 
and two studies have reported higher latency-based IIV in patients with lesions in the dlPFC (Stuss et al., 
2003) and patients with frontotemporal dementia (Murtha et al., 2002). However, other studies have 
failed to observe similar associations (Lövdén et al., 2013; Moy et al., 2011; Ullen et al., 2008; Walhovd 
& Fjell, 2007). At the time being, neither the literature nor the present results allow general conclusions 
about gray matter volumes representing structural brain correlates of accuracy-based IIV in general, and 
within-domain IIV in particular. Based on the present results, however, we can conclude that such a 
relationship does not exist in MCI-S or MCI-CB. 
We have already discussed the limiting influences of early disease stages, relatively small subject 
numbers and the low characteristic utility of within-domain IIV on our analyses. The unknown number of 
HCS that will convert to MCI and of MCI-S that will convert to AD in the future represents another 
limiting factor of the present study. Despite the rather high mean follow-up times (see Table 3) in both 
groups, we cannot rule out the possibility of future conversions. Furthermore, the comparison of our 
results with the IIV literature is complicated by varying definition of accuracy-based IIV across studies. 
We calculated IIV across accuracy scores obtained from tasks eliciting cognitive control processes and 
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representing executive functions (within-domain IIV). Others have calculated IIV across accuracy scores 
from tasks representing different cognitive domains (across-domain IIV) (Holtzer et al., 2008; Kälin et 
al., 2014; MacDonald et al., 2012; Tractenberg & Pietrzak, 2011; Vaughan et al., 2013) or across 
accuracy scores from tasks representing the same domain, but not executive functions (Ramratan et al., 
2012). Although there is yet no empirical basis for this assumption, within- and across-domain IIV may 
represent different measurements (for a discussion see Kälin et al., 2014), and the comparison of results 
across IIV studies poses a challenge. 
We conclude that the potential value of within-domain IIV as early marker for AD is questionable. 
Studies consisting of much higher sample sizes compensating for the low characterization of within-
domain IIV may provide further information. Within-domain IIV, however, does not seem to be 
associated with prefrontal and parietal gray matter cortex volumes in MCI-CB. Additional research 
including AD patients showing further progressed atrophy is required to investigate the relationship 
between within-domain IIV and AD related gray matter atrophy in IIV-relevant brain regions.  
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5.3.1 Abstract  
 
Treatment methods currently under investigation at onset of prodromal stages of Alzheimer’s disease 
(AD) will require biomarkers that differentiate between patients with stable mild cognitive impairment 
and patients who will convert to AD in the future. Here, we applied recently developed analyses 
techniques to investigate differences in subcortical shape and volume alterations in patients with stable 
mild cognitive impairment (MCI-S, n=23, age range 59-82, 47.8% female), future converters at baseline 
(MCI-CB, n=10, age range 66-84, 90% female) and at time of conversion (MCI-CC, age range 68-87) 
compared to group-wise age and gender matched healthy control subjects (HCS, n=23, age range 61-81, 
47.8% female; n=10, age range 66-82, 80% female; n=10, age range 68-82, 70% female). Additionally, 
sophisticated analyses techniques were used to further confirm cortical thinning and global and local 
measures of hippocampal atrophy as these are known key imaging markers for AD. Apart from bilateral 
striatal volume reductions, no morphometric alterations were found in MCI-S. In contrast, we identified 
shape alterations in striatal (caudate head, caudate body, ventral medial and ventral lateral putamen) and 
thalamic regions (anterior, posterior and medial dorsal thalamus) in MCI-CB and MCI-CC. The shape 
alterations were paralleled by AD-like patterns of left hemispheric morphometric changes (cortical 
thinning in medial temporal regions, hippocampal total and subfield atrophy) in MCI-CB with 
progression to similar right hemispheric alterations in MCI-CC. The present results further confirm the 
key role of early cortical thinning and hippocampal atrophy in the early detection of AD. But first and 
foremost, and by distinguishing MCI-CB but not MCI-S from HCS, our results support the value of early 
subcortical shape alterations and reduced hippocampal subfield volumes as potential markers for the early 
detection of AD. 
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5.3.2 Introduction   
 
Alzheimer’s disease (AD) is a neurodegenerative brain disorder characterized by progressive dementia, 
with current treatments providing only temporary symptomatic stabilisation. Improved treatment methods 
that are currently under investigation may be most efficacious in preclinical or early disease stages (Golde 
et al., 2011; Sperling, Jack, et al., 2011), referred to as mild cognitive impairment (MCI). In particular, 
subjects of the amnestic MCI subtype (aMCI) are more likely to progress to AD than subjects of the non-
amnestic subtype (Roberts et al., 2014). However, the development of cognitive and clinical symptoms 
varies even among aMCI. Some subjects develop dementia other than AD, whereas others remain stable 
for a long time or even recover (Roberts et al., 2014). Thus, the establishment and validation of 
biomarkers that accurately identify future converters to AD is crucial. 
Structural magnetic resonance imaging (MRI) represents a key imaging marker for the early detection of 
AD. It allows the quantification of brain atrophy due to early involvement of neurofibrillary tangle 
formation followed by neuronal loss. Specifically, reduced gray matter volume in medial temporal lobe 
regions including the hippocampal formation may precede clinical onset of AD by ten years (Tondelli et 
al., 2012). Consequently, the applicability of hippocampal subfield segmentation in clinical populations 
has gained increasing attention, with different studies providing evidence for predominant cornu ammonis 
(CA) 1 and subiculum atrophy in MCI (Apostolova, Dutton, Dinov, & et al., 2006; Atienza et al., 2011; 
La Joie et al., 2013; Pluta et al., 2012; Yushkevich et al., 2014) and AD (Apostolova, Dinov, et al., 2006; 
Frankó et al., 2013; Frisoni et al., 2008; Mueller et al., 2010; Mueller & Weiner, 2009; Wisse, Biessels, 
Heringa, et al., 2014). Although the number of studies investigating hippocampal subfields in future 
converters is limited, results obtained by applying surface-based subfield mapping techniques have shown 
similar atrophy patterns already in healthy control subjects (HCS) who later developed MCI (Apostolova 
et al., 2010), and in MCI who later developed AD (Apostolova, Dutton, et al., 2006; Frankó et al., 2013). 
Given these few findings, it is crucial to gain more information about volumetric changes of hippocampal 
subfields in individuals at high risk for conversion to AD. 
Cortical thinning constitutes another widely accepted approach to measure gray matter atrophy in AD 
(Lerch & Evans, 2005). Different fully automated approaches with varying degrees of precision in terms 
of cortical thickness definition have been developed (e.g. MacDonald et al., 2000). Irrespective of the 
definition, however, cortical thinning has been found in patients with MCI and AD (Lerch, Pruessner, et 
al., 2008; Liao et al., 2014), in late versus early aMCI (Ye et al., 2014), and in future converters (Bakkour 
et al., 2009; Julkunen et al., 2010; Li et al., 2012; Liao et al., 2014).  
Despite evidence for subcortical amyloid and neurofibrillary tangle formation (Braak & Braak, 1990, 
1991b), MRI research has drawn its attention to subcortical structure changes only recently. Advanced 
segmentation techniques now permit the quantification of subcortical volumes and provide the basis for 
subcortical shape analyses. Although volume loss and/or shape alterations in the thalamus (Roh et al., 
2011; Stepan-Buksakowska et al., 2014; Zarei et al., 2010), putamen (Cho et al., 2014; de Jong et al., 
2014; Roh et al., 2011) and caudate nucleus (Cho et al., 2014; Madsen et al., 2010; Roh et al., 2011) have 
been identified in AD, only little is known about subcortical volumetric and shape differences in MCI in 
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general, and in future converters in particular. Recent results of amyloid-associated subcortical alterations 
already in cognitively normal elderly (Schreiner et al., 2014) further emphasize the relevance of these 
structures in AD. Given their connection to other AD-relevant structures such as the hippocampus (Zarei 
et al., 2010), the thalamus and striatum in particular represent subcortical structures of interest for being 
investigated in early AD.  
Here, we investigated morphometric alterations in MCI with stable cognitive abilities, in MCI with future 
conversion to AD at baseline and at time of conversion. The multi-atlas based method used for the 
segmentation (hippocampus and subfields; thalamus and subnuclei; striatum) has previously evidenced 
improved segmentation when tested against model-based segmentation procedures (Chakravarty et al., 
2013). Shape changes in the thalamus and the striatum were investigated by using an extension of a 
previously proposed (Lerch, Carroll, et al., 2008) and recently established (Leh et al., 2014; Magon et al., 
2014; Raznahan et al., 2014; Shaw, Sharp, et al., 2014) surface-based methodology. Cortical thickness 
was assessed by applying a fully automated algorithm using a highly precise cortical thickness definition 
(Lerch & Evans, 2005). Based on these advanced techniques, we aimed to gain information about the 
potential value of morphometric measures to improve the identification of future converters to AD.  
Confirming ongoing AD related neurodegenerative processes, morphometric alterations were expected to 
occur in future converters at baseline with more pronounced alterations at time of conversion. In contrast, 
stable MCI subjects were expected to show only minimal or no alterations at all. Specifically, the pattern 
of AD-related neurofibrillary tangle formation indicates early pathology in anterior thalamic regions as 
well as hippocampal subfield CA1 followed by the subiculum and later involvement of CA2 and CA3 
(Braak & Braak, 1990, 1991a, 1991b). Accordingly, we expected volume reductions in the hippocampus, 
thalamus and striatum, as well as in particular hippocampal (CA1, subiculum) and thalamic (anterior) 
subregions. Further confirming AD-related neurodegenerative patterns and the literature (Liao et al., 
2014), we expected cortical thinning in mediotemporal as well as lateral cortical regions in future 
converters at baseline and at time of conversion. Most importantly, we assumed thalamic and striatal 
shape alterations to occur in both groups as well. The neuronal basis of shape alterations is yet unknown. 
However, subcortical volume reductions as well as possible secondary downstream effects may lead to 
thalamic and striatal shape alterations. 
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5.3.3 Methods 
 
Participants 
We selected participants from pre-existing longitudinal cohorts at the Memory Clinic of the Division of 
Psychiatry Research and Psychogeriatric Medicine, University of Zurich. MCI was diagnosed according 
to Winblad et al. (2004). Conversion to dementia was diagnosed when subjects met National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria for probable AD (McKhann et al., 1984). All 
diagnoses were made by a multidisciplinary team under the supervision of an experienced psychiatrist.  
For the present study, inclusion criteria for MCI subjects were: aMCI diagnosis and availability of MRI 
data at baseline and follow-up. Exclusion criteria were: left-handedness, significant medication or drug 
abuse as well as clinically significant neurological and psychiatric or internal disease that may affect 
cognition, MRI exclusion criteria, MRI findings of infarction or other focal lesions, multiple lacunes or 
lacunes in critical memory structures.  
A total of 41 baselines from subjects with aMCI were considered for the present study.  Eight subjects 
were excluded from the analyses due to left-handedness (n=5), structural abnormalities in the brain (n=1), 
and T1 parameters that were inconsistent with the MRI study protocol (n=2). The remaining population 
was stratified into subjects with stable cognitive abilities during an approximately 2-year follow-up 
(MCI-S, n=23), and subjects with future cognitive worsening and conversion to probable AD (converter 
at baseline MCI-CB, n=10) during an approximately 2-year follow-up. Additionally, data from the MCI-
CB group at time of conversion was obtained (MCI-CC, n=10). Inclusion criteria for HCS were: stable 
cognitive health ascertained by clinical work up and neuropsychological testing during an approximately 
2-year follow-up. Exclusion criteria were: left-handedness, evidence for abuse of alcohol and drugs, 
psychiatric, neurological or significant other system diseases. Three groups of HCS were identified for 
group wise age and gender matching with MCI-S, MCI-CB, and MCI-CC. The final demographic details 
are presented in Table 5. This study was approved by the cantonal ethics committee of canton Zurich, 
Switzerland, in accordance with the Helsinki Declaration. All participants provided written informed 
consent prior to study inclusion. 
 
Magnetic resonance image acquisition  
All scans were performed on the same 1.5 Tesla Phillips Achieva scanner using an 8-element head coil. 
Whole-brain high-resolution three-dimensional (3D) T1-weighted structural data was obtained by using 
the following scanning parameters: 166 slices, repetition time: 6.9 milliseconds, echo time: 3.2 
milliseconds, flip angle: 8°, field of view: 240 x 240 x 166 millimeters (anterior-posterior, foot-head, 
right-left), slice thickness: 1 millimeter, total scan time: 15 min. 
 
 
54 
 
Image processing: subcortical structures and hippocampus  
Segmentation of the striatum, thalamus and its subnuclei was performed by using a newly developed 
label-fusion-based segmentation method that has previously proved its high accuracy (Chakravarty et al., 
2013; Leh et al., 2014). Briefly, the MAGeT-Brain algorithm applies multiple automatically generated 
templates from a single atlas derived from manually segmented serial histological data (Chakravarty et 
al., 2006) comprising 108 basal ganglia and thalamic structures as defined using three different references 
(Gloor, 1997; Hirai & Jones, 1989; Schaltenbrand & Wahren, 1977). We used two of the segmentations 
produced from the MAGeT-Brain pipeline, the first are the whole striatum (caudate and putamen) and 
thalamus, and the second are the thalamic subnuclei as per the Hirai and Jones (1989) definitions. The 
thalamus was segmented into pulvinar-, anterior-, and central nuclei and lateral dorsal-, lateral posterior-, 
medial dorsal nuclei, ventral anterior (VA)-, ventral lateral (VL)-, ventral posterior (VP) nuclei and lateral 
geniculate nucleus (LGN) and medial geniculate nucleus (MGN) as per the Hirai and Jones (1989) 
nomenclature. Segmentation of the hippocampus and its subfields was performed using five high-
resolution atlases developed and validated for use with MAGeT-Brain (Pipitone et al., 2014; Winterburn 
et al., 2013). The hippocampus was segmented into CA1, CA2-CA3, CA4/Dentate gyrus, strata 
radiatum/lacunosum/moleculare, and subiculum.  
Furthermore, total incranial volume (eTIV) was estimated following a previously validated procedure 
(Buckner et al., 2004).  
 
Surface-based shape analyses 
Striatal and thalamic shape analysis was performed by using an adapted surface-based methodology (Leh 
et al., 2014; Lerch, Carroll, et al., 2008; Magon et al., 2014; Raznahan et al., 2014; Shaw, Sharp, et al., 
2014). Briefly, surface-based representations of the striatum and thalamus were defined on the input atlas. 
The nonlinear portions of the transformations that map each subject to the input template were 
concatenated and then averaged to limit the effects of noise and error and to increase precision and 
accuracy. Next, the dot product between the nonlinear deformation vector (of the inverse of the averaged 
atlas-to-subject transformation) and the surface normal at each vertex (a unit vector describing the 
direction perpendicular to the surface) was estimated. This measure provides an estimate of the local 
measure of inward or outward displacement along the normal. Resulting inward and outward 
displacements (measured in millimeters) were estimated relative to a detailed subcortical atlas previously 
described (Chakravarty et al., 2006). An inward displacement (contraction) represents a surface that is 
deformed inwards relative to the model that we were using and vice-versa for the outward displacement 
(expansion). 
 
Cortical thickness analyses 
Cortical thickness was estimated by using the automated CIVET pipeline (version 1.1.10; Montreal 
Neurological Institute at McGill University, Montreal, Quebec, Canada) (Ad-Dab'bagh et al., 2006). 
Briefly, the native images were linearly registered to the symmetric ICBM 152 template (Collins et al., 
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1994; Mazziotta et al., 2001). Intensity non-uniformities were corrected using the N3 algorithm (Sled et 
al., 1998). The skull was removed (Smith, 2002), and brain tissue was segmented into white matter, gray 
matter, cerebrospinal fluid (CSF) using the Intensity- Normalized Stereotaxic Environment for 
Classification of Tissues (INSECT) algorithm (Tohka et al., 2004; Zijdenbos et al., 1998). Deformable 
models were used to construct the inner white matter surface and gray matter-CSF interface in both 
hemispheres (Kim et al., 2005) revealing 40,962 vertex points at each surface. Cortical thickness was then 
measured as the distance, in millimeters, between each vertex point at the inner and the corresponding 
point at the outer surface using the method proposed by Lerch and Evans (2005). The cortical thickness 
maps were blurred using a 20mm diffusion smoothing kernel (Chung & Taylor, 2004) to increase signal-
to-noise ratio and statistical power. 
 
Statistical analyses 
Group comparisons of demographic data were applied using analysis of variance (ANOVA) or Mann-
Whitney U Test. Pearson’s chi-square test was used for categorical variables. Between-group differences 
in volumetric raw data (MCI-S, MCI-CB and MCI-CC versus matched HCS) were examined by 
including age and gender as covariates in the multiple linear regression models. These analyses were 
repeated by using volumes relative to eTIV (volume/eTIV * 100) in order to adjust volumes for 
differences in head size. P values resulting from volume analyses were adjusted for multiple testing by 
using Bonferroni Holms correction. Tests were performed with a significance level of p<0.05. The same 
models were performed for investigating between-group shape and cortical thickness differences. Vertex-
wise analyses results are reported on a q-value corrected for multiple testing, using a false discovery rate 
(FDR) rate of 10% as in previous publications in our group (Janes, Park, Farmer, & Chakravarty, 2014). 
Statistical analyses were performed with IBM SPSS statistics 21 and RMINC package (R for Medical 
Imaging NetCDF; https://github.com/Mouse-Imaging-Centre/RMINC), an image analysis software 
library developed for the R statistical environment (http://www.r-project.org).  
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5.3.4 Results 
 
Demographics 
Descriptive statistics for demographic information is listed in Table 5. There were no significant 
differences in terms of age, education and gender between patient groups and controls. However, all 
patient groups showed significantly lower MMSE scores than their controls (Group 1 U=100.5, p=.000; 
Group 2 U=7.500, p=.000; Group 3 U=.500, p=.000). 
 
Volumetric analyses in MCI-S 
Apart from reduced bilateral striatal volumes (left t=2.59, p=.013; right t=2.91, p=.006, df=3,42), and 
when analyzing volumes relative to eTIV, there were no volume differences in any of the investigated 
structures in MCI-S (Table 6). Significance and p-values were similar when using raw volumes instead of 
volumes relative to eTIV (Supplementary Table 1). A segmentation map of the thalamus is shown in 
Figure 3, and of the hippocampus in Figure 4. 
 
Volumetric analyses in MCI-CB  
In contrast, pronounced reductions in volumes relative to eTIV were found in MCI-CB (see Table 6). In 
particular, and apart from CA2-CA3 volumes, all bilateral hippocampal subfield volumes were smaller in 
MCI-CB compared to HCS (right CA1 t=3.23, p=.005; subiculum t=3.29, p=.005; CA4/Dentate gyrus 
t=3.80, p=.002; strata t=4.55, p=.000 / left CA1 t=5.18, p=.000; subiculum t=4.96, p=.000; CA4/Dentate 
gyrus t=4.66, p=.000; strata t=5.91, p=.000; df=3,16) (Figure 5). With regard to thalamic subnuclei, and 
although statistically significant, effects of volume reductions in bilateral VP in MCI-CB (right p=.047, 
left p=.015) did not survive the correction for multiple testing. Significance and p-values were similar 
when using raw volumes instead of volumes relative to eTIV. However, some of the right hemispheric 
differences in hippocampal subfield volumes did not quite achieve the level of significance (CA1 
p=.057). Additionally, and although statistically significant, two right hemispheric effects did not survive 
the correction for multiple comparisons (CA4/Dentate gyrus p=.017; subiculum p=.027) (Supplementary 
Table 1). 
 
Volumetric analyses in MCI-CC 
Further extended reductions in volumes relative to eTIV occurred in MCI-CC (see Table 6). More 
precisely, all bilateral hippocampal subfield volumes were smaller in MCI-CC compared to HCS (left 
CA1 t=5.09, p=.000; subiculum t=5.00, p=.000; CA2-CA3 t=4.01, p=.001; CA4/Dentate gyrus t=6.66, 
p=.000; strata t=9.41, p=.000 / right CA1 t=3.24, p=.005; subiculum t=3.91, p=.001; CA2-CA3 t=2.18, 
p=.044; CA4/Dentate gyrus t=4.47, p=.000; strata t=5.53, p=.000; df=3,16) (Figure 5). Similar as in MCI-
CB, effects of VP volume reductions in MCI-CC (right p=.054, left p=.009) did not survive the correction 
for multiple testing. Significance and p-values were similar when using raw volumes instead of volumes 
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relative to eTIV. However, two right hemispheric effects in hippocampal subfield volumes did not quite 
achieve the level of significance (CA1 p=.074; CA2-CA3 p=.057) (Supplementary Table 1).  
 
 
 
 
Figure 3  Automated segmentation of thalamic subnuclei. Surface labels for thalamic subnuclei, based on 
expert neuroanatomical labeling of serial histology (Chakravarty et al., 2006). Figure reproduced with 
kind permission of Leh et al. (2014). 
 
 
 
 
Figure 4  Automated segmentation of hippocampal subfields. CA = cornu ammonis. Coronal views of the 
hippocampus and hippocampal subfields in magnetic resonance images from a healthy control subject 
(HCS) and a mild cognitive impairment converter at time of conversion (MCI-CC).  
58 
 
 
59 
 
Figure 5  Reduced left hippocampal total and subfield volumes in future converters at baseline and at 
time of conversion. Subjects with stable mild cognitive impairment (MCI-S) exhibited similar 
hippocampal total and subfield volumes whereas future converters at baseline (MCI-CB) showed reduced 
hippocampal volume and reduced volumes in all but one (cornu ammonis [CA]2-CA3) hippocampal 
subfields when compared with healthy control subjects (HCS). Correspondingly, converters at time of 
conversion (MCI-CC) showed reduced hippocampal volume and reduced volumes in all hippocampal 
subfields. Data is only shown for the left hemisphere. Results are similar for the right hemisphere though. 
* p ≤ .001 significant p value test by using volumes relative to eTIV as dependent variable, and including 
age and gender in the model. Results were corrected for multiple testing and were similar when analyses 
were performed by using raw volumes as dependent variable. However, some of the right hemispheric 
differences in hippocampal subfield volumes did not quite achieve the level of significance in MCI-CB 
versus HCS (CA1 right p=.057) and in MCI-CC versus HCS (CA1 right p=.074; CA2-CA3 right p=.057). 
Additionally, and although statistically significant, two effects did not survive the correction for multiple 
comparisons in MCI-CB versus HCS (CA4/Dentate gyrus right p=.017; subiculum right p=.027). 
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Vertex-wise cortical thickness analyses in MCI groups  
Analyses on data corrected for multiple testing by using FDR at q<.10 revealed no cortical thinning in 
MCI-S compared to HCS. Reduced cortical thickness, however, was found in MCI-CB and MCI-CC 
(Figure 6, Table 7). Significant effects were limited to medial parts such as the left parahippocampal 
cortex, left subgenual cingulate, and left region of the uncus in MCI-CB. Similar regions showed cortical 
thinning in the right hemisphere, with significance only at q<.15 though (Figure 6). Importantly, the 
pattern of cortical thinning extended to the right hemisphere in MCI-CC, where cortical thinning in 
bilateral parahippocampal cortices and bilateral regions of the uncus now achieved an appropriate level of 
significance. 
 
 
 
 
Figure 6  Reduced cortical thickness in future converters at baseline (MCI-CB) and at time of conversion 
(MCI-CC) but not in subjects with stable cognitive abilities (MCI-S) when compared with healthy control 
subjects (HCS). Images were generated after including age and gender in the model, and after correction 
using the False Discovery Rate (FDR) at q=.15 to better illustrate the anatomical localization. Bar shows 
the FDR-values, with blue – light blue indicating reduced cortical thickness. 
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Table 7  Reduced cortical thickness in patients groups  
 
A 
Anatomic localization MNI coordinates (peak) t statistic (peak) 
  x y z  
     
Parahippocampal Cortex, left -30 -16 -27 -5.77** 
Subgenual Cingulate, left -18  15 -14 -4.34** 
Uncus, left -29 -29   -8 -6.53** 
     
 
B 
Anatomic localization MNI coordinates (peak) t statistic (peak) 
  x y z  
     
Parahippocampal Cortex, left -25 -13 -32 -7.13** 
Uncus, left -31 -12 -23 -7.06** 
Parahippocampal Cortex, right  29 -12 -28 -5.45* 
Uncus, right  31 -10 -22 -5.20* 
     
 
Note. Anatomical localization of cortical thinning in mild cognitive impairment converter at baseline (A), 
and in mild cognitive impairment converters at time of conversion (B). * significant after including age 
and gender in the model, and after correction using False Discovery Rate at q<.10. ** significant after 
including age and gender in the model, and after correction using False Discovery Rate at q<.01. 
 
 
Vertex-wise subcortical shape analyses in MCI groups  
Analyses on data corrected for multiple testing by using FDR at q<.10 showed no striatal or thalamic 
shape alterations in MCI-S, but pronounced striatal and thalamic displacements in MCI-CB and MCI-CC 
compared to HCS. 
Thalamic contractions and expansions are presented in Figure 7A. In contrast to MCI-S, MCI-CB and 
MCI-CC showed contractions which were limited to dorsal and medial parts, and were more pronounced 
in the left than in the right hemisphere. Specifically, MCI-CB exhibited contractions in bilateral dorsal 
aspects of the pulvinar, bilateral dorsal aspects of VP, and in left medial aspects of VP and medial dorsal 
nuclei. Again, the pattern of alterations had further continued in MCI-CC, exhibiting more pronounced 
contractions extending from dorsal aspects of the pulvinar and VP to dorsal aspects of VL, lateral 
posterior nuclei, and VA in the right hemisphere. In contrast, contractions in the left hemisphere were 
now limited to dorsal aspects of VL, VA, and medial dorsal nuclei. However, there was a tendency 
towards significant contractions (q=.15) in dorsal aspects of the pulvinar, VP and lateral posterior nuclei 
as well. Thalamic expansions in turn were limited to ventral and medial parts. MCI-CB showed 
expansions in bilateral ventral aspects of the central nuclei, VA, VL and VP. MCI-CC showed the same, 
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though more pronounced pattern of expansions in both hemispheres, with additional expansion in the 
medial aspect of the medial dorsal nuclei. 
Striatal displacements are presented in Figure 7B. Again in contrast to MCI-S, the other groups displayed 
contractions, predominantly in the left hemisphere and most pronounced in ventral (inferior) aspects. 
More precisely, MCI-CB showed contractions in medial parts of the putamen and anterior parts of the 
striatum (caudate head). The same pattern was found in MCI-CC, with more pronounced alterations in 
left ventral (inferior) medial parts of the putamen and with continued spreading to the left dorsal medial 
striatum (caudate body) and to right ventral (inferior) aspects of the anterior striatum (caudate head). 
Similar to the contractions, striatal expansions were more pronounced in the left hemisphere: MCI-CB 
showed pronounced expansions in ventral aspects of the anterior striatum (caudate head) and lateral 
putamen. MCI-CC showed a similar pattern, but with further continued expansions to ventral (inferior) 
aspects of the left striatum (caudate tail), and to ventral aspects of the anterior striatum (caudate head) of 
the right hemisphere. 
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Figure 7  Regions of significant thalamic and striatal shape alterations in future converters at baseline 
(MCI-CB) and at time of conversion (MCI-CC) when compared with healthy control subjects (HCS). 
Images for differences in thalamic displacements (A) and striatal displacements (B) between groups were 
generated after including age and gender in the model, and after correction using the False Discovery 
Rate (FDR) at q=.15 to better illustrate the anatomical localization. Bars show FDR rate-values, with blue 
– light blue indicating inward displacements (contractions) and pink – light pink indicating outward 
displacements (expansions).  
  
67 
 
5.3.5 Discussion 
 
In the current study we applied newly developed and already well-established structural imaging 
techniques which allowed us to characterize future converters to AD through cortical thinning, 
hippocampal total and subfield atrophy as well as thalamic and striatal shape alterations already at 
predementia stage. 
 
Cortical thinning in future converters   
Cortical thinning was not present in MCI-S compared to HCS. As expected, however, we found 
pronounced cortical thinning in left parahippocampal regions including the uncus in MCI-CB with further 
progression to bilateral regions in MCI-CC. This pattern is consistent with Braak staging (Braak & Braak, 
1991b) and with memory impairment associated morphometric changes in early AD (Drago et al., 2011; 
Venneri, McGeown, et al., 2011).  
Additionally, our results are in agreement with other studies reporting prominent thinning in 
parahippocampal regions in future converters (Julkunen et al., 2010; Li et al., 2012). Moreover, thinning 
in this region has been reported faster in future converters than in non-converters (Li et al., 2012), and 
being present in AD (Julkunen et al., 2010; Lebedev et al., 2013; Lerch, Pruessner, et al., 2008; Li et al., 
2012). Similarly, atrophy in regions of the uncus has been identified in MCI (Venneri, McGeown, et al., 
2011) and AD (Hartikainen et al., 2012; Rami et al., 2012). Like others (Lebedev et al., 2013), we also 
identified cortical thinning in the subgenual cingulate region in MCI-CB. Functionally, this region has 
been related to normal sadness reactions (Phan, Wager, Taylor, & Liberzon, 2002), and reduced volumes 
have been observed in patients with major depressive disorder (Drevets, Price, & Furey, 2008). Although 
clinically significant depression was one of the exclusion criteria in our study, very subtle but not 
measurable depressive symptoms in MCI-CB may have triggered this finding. The subgenual region has 
furthermore been associated with the uptake of serotonin (Lanzenberger et al., 2013). Serotonin is 
involved in the regulation of sleep (Portas, Bjorvatn, & Ursin, 2000) which is disturbed in AD 
(Westerberg et al., 2012). 
However, our results of cortical thinning being limited to medial regions are in contrast to our expectation 
and the literature. Others have described more widespread, though heterogeneous patterns of cortical 
thinning covering not only medial but also lateral cortical regions including inferior, middle and superior 
temporal regions (Bakkour et al., 2009; Julkunen et al., 2010; Li et al., 2012; Liao et al., 2014), inferior 
and superior parietal lobe regions (Bakkour et al., 2009; Julkunen et al., 2010; Li et al., 2012; Liao et al., 
2014) and inferior and superior frontal lobe areas (Dickerson et al., 2009; Julkunen et al., 2010; Li et al., 
2012; Liao et al., 2014) in future converters and in AD patients. Nevertheless, also Julkunen and 
colleagues (2010) have documented cortical thinning in MCI-CB being limited to medial temporal 
regions. But in contrast to our own findings, their AD subjects have shown an extended pattern of lateral 
thinning. The limitation of cortical thinning to medial parts in our MCI-CC is most likely related to the 
fact that this group comprises the same subjects as MCI-CB at time of conversion and hence, at very early 
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disease stages. In contrast, AD and MCI groups consisted of different subjects in other studies (Julkunen 
et al., 2010; Li et al., 2012; Liao et al., 2014), with AD patients presumably representing advanced 
disease stages.  
 
Hippocampal atrophy in future converters  
MCI-S revealed no global or local hippocampal volume reductions compared to HCS. However, in 
accordance with the AD literature (Ferrarini et al., 2014; Stepan-Buksakowska et al., 2014) and our 
expectations, we found reduced volumes of bilateral hippocampi in MCI-CB and MCI-CC. But first and 
foremost, we found reduced local volumes of all but one (CA2-CA3) bilateral subfields already in MCI-
CB, and of all bilateral subfields in MCI-CC.  
Hippocampal shrinking represents the key imaging marker in AD research. The successful identification 
of hippocampal subfields by using high-field MRI, however, has offered a more local approach 
(Antharam et al., 2012; Mueller et al., 2010; Mueller & Weiner, 2009; Wisse, Biessels, Heringa, et al., 
2014; Yushkevich et al., 2009). Advances in segmentation and analyses techniques have now enabled the 
field to identify hippocampal subfield alterations on images obtained from clinical standard systems. 
Corresponding with the pattern of neurofibrillary tangle formation, predominant CA1 atrophy has been 
found in MCI (Apostolova, Dinov, et al., 2006; Atienza et al., 2011; La Joie et al., 2013; Pluta et al., 
2012; Yushkevich et al., 2014), with some of these studies having reported additional subicular alterations 
(Atienza et al., 2011; La Joie et al., 2013). A more extended pattern also including CA2 and CA3 or even 
CA4/Dentate gyrus has been identified in AD (Apostolova, Dinov, et al., 2006; Frankó et al., 2013; 
Frisoni et al., 2008; Li et al., 2013). Importantly, alterations in these subfields have been related to 
impaired memory functions in aMCI (Atienza et al., 2011; Ferrarini et al., 2014). Local analysis of the 
structure, therefore, has been suggested advantageous for the early detection of dementia (Tang et al., 
2014).   
Nevertheless, only a few studies have examined hippocampal subfields in future converters. Even though 
they have applied surface-based subfield imaging without providing volumetric information, results of 
alterations in CA1 and/or subiculum in future converters to MCI (Apostolova et al., 2010) or to AD 
(Apostolova, Dutton, et al., 2006; Chételat et al., 2008; Frankó et al., 2013) are in agreement with our 
own findings. In line with further progression of tangle accumulation (Braak & Braak, 1991b), we found 
similar bilateral CA2-CA3 volumes in MCI-CB but reduced bilateral CA2-CA3 volumes in MCI-CC 
compared to HCS. Additionally, we found bilateral CA4/Dentate gyrus volumes being lowered not only 
in MCI-CC but also in MCI-CB. Although this results contrasts the assumed spatial progression of tangle 
distribution in MCI-CB, similar findings have been reported by others (Pluta et al., 2012). We also 
identified reduced volumes of bilateral strata lacunosum/radiatum/moleculare in MCI-CB and MCI-CC, 
and our results are supported by studies reporting stratum radiatum and stratum lacunosum/moleculare of 
CA1 being affected by early tangle accumulation (Braak & Braak, 1997; Braak, Alafuzoff, Arzberger, 
Kretzschmar, & Del Tredici, 2006; Thal et al., 2000) and atrophy in mild AD (Kerchner et al., 2010). 
Method wise, it has to be noted that only a few protocols exist allowing for the reliable, automated 
segmentation of hippocampal subfields (see Wisse, Biessels, & Geerlings, 2014 for a critical discussion). 
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Here, we used a multi-atlas based segmentation approach (Chakravarty et al., 2013) that has recently 
evidenced high reliability and to perform equally well and probably better than other established methods 
(Pipitone et al., 2014). 
 
Thalamic shape alterations in future converters 
MCI-S did not reveal any deviation from HCS, neither in thalamic total or subfield volumes nor in shape 
alterations. 
Interestingly, and against our expectation, the same was true for both, total and local thalamus volumes in 
MCI-CB and MCI-CC. To date, the reliable identification of thalamic subnuclei has been addressed by 
using diffusion tensor imaging techniques at 1.5 Tesla (Kumar, Mang, & Grodd, 2014; Lyness, Alvarez, 
Sereno, & MacSweeney, 2014; Zarei et al., 2010), and by applying new image processing techniques on 
data acquired from 1.5 up to 7 Tesla systems to visualize some of the nuclei (Abosch, Yacoub, Ugurbil, & 
Harel, 2010; Bender, Manz, Korn, Nagele, & Klose, 2011; Deoni, Josseau, Rutt, & Peters, 2005; 
Kanowski et al., 2014). Reports about detailed segmentation and quantification of thalamic subnuclei 
volumes in MCI and AD, however, are rare. Different studies have indeed reported reduced thalamic total 
volumes in MCI-CB (Bossa et al., 2011) and AD (de Jong et al., 2008; Roh et al., 2011; Stepan-
Buksakowska et al., 2014; Zarei et al., 2010). Nevertheless, thalamic atrophy in AD is debated, 
particularly in early disease stages (Braak & Braak, 1991a; Paskavitz, Lippa, Hamos, Pulaski-Salo, & 
Drachman, 1995; Xuereb et al., 1991), where only a few regions are affected by a small number of 
isolated neurofibrillary tangles (Braak & Braak, 1991b). Hence, it is not surprising that there was only a 
trend toward reduced VP volumes in MCI-CB and in MCI-CC. Accordingly, our results are in agreement 
with other studies having observed similar volumes in aMCI (Leh et al., 2014), MCI  and AD patients 
(Cho et al., 2014; Tang et al., 2014).  
But first and foremost, and despite the absence of volumetric differences, we identified a widespread 
pattern of shape alterations in MCI-CB and MCI-CC. Confirming our expectation, the pronounced 
thalamic shape alterations in VA found in MCI-CB and MCI-CC cover regions that are affected from 
early neurofibrillary tangles and later occurring amyloid deposition (Braak & Braak, 1991b). Importantly, 
the thalamus plays a crucial role in the Papez circuit with the anterior thalamus and the pulvinar, both 
having shown shape alterations in MCI-CB and MCI-CC, being directly connected to the hippocampus 
(Zarei et al., 2010). Furthermore, frontostriatal circuits link dorsolateral prefrontal, anterior cingulate, and 
orbitofrontal cortex regions (Alexander, DeLong, & Strick, 1986) via the striatum and globus pallidus 
(Haber, 2003) to VA and medial dorsal aspects of the thalamus (Bonelli & Cummings, 2007; Tekin & 
Cummings, 2002), aspects that again have showed shape alterations in MCI-CB and MCI-CC. Further 
significant shape alterations were found in the VP, VL and lateral posterior nuclei connecting the 
structure with the somatosensory, motor, premotor and prefrontal and temporal and parietal cortices 
(Behrens et al., 2003; de Bourbon-Teles et al., 2014). Consistent with these extensive connections, 
thalamic regions affected from shape alterations in MCI-CB and MCI-CC have been linked with memory 
and frontal executive, attention, visuospatial perception, and emotion processing (Arend et al., 2014; 
de Bourbon-Teles et al., 2014; Saalmann, 2014; Wilke et al., 2013), with all of these functions being 
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impaired early in AD (Klekociuk et al., 2014). Moreover, thalamic shape alterations similar to the ones in 
the present study have been found to be significantly correlated with learning abilities in aMCI in a recent 
study from our own group (Leh et al., 2014). 
To our knowledge at present, there is only one study that has investigated subcortical shape alterations in 
MCI-S and MCI-CB, however, without comparing their data to HCS (Tang et al., 2014). Nevertheless, 
the contractions found in the pulvinar and dorsal aspects of the VP in MCI-CB are consistent with 
contractions that have been identified in aMCI by an earlier study of our group (Leh et al., 2014). 
Additionally, the authors have documented contractions in regions that remained unaffected in the present 
MCI-CB sample such as the VL and lateral posterior nuclei. These, however, showed contractions in the 
MCI-CC group. Our finding of contractions in the pulvinar and dorsal as well as medial dorsal regions in 
MCI-CC in turn is consistent with other study results (Cho et al., 2014; Qiu, Fennema-Notestine, Dale, & 
Miller, 2009; Stepan-Buksakowska et al., 2014). Results about thalamic expansions in MCI and AD are 
few and inconsistent. In contrast to expansions in ventral regions in both MCI-CB and MCI-CC, the 
earlier study from our group has identified expansions in more lateral aspects in aMCI, whereas others 
have reported expansions in medial or even dorsal aspects in MCI and AD (Qiu et al., 2009; Tang et al., 
2014). Further studies are warranted to find out whether there are typical thalamic expansion patterns for 
AD. 
 
Striatal shape alterations in future converters 
Surprisingly, and against our expectation, we observed reduced bilateral striatal volumes in MCI-S but 
similar volumes in MCI-CB and MCI-CC when compared to HCS. The most probable assumption of age- 
and gender-related shrinking or age-related changes in dopamine and frontostriatal networks (Abedelahi, 
Hasanzadeh, Hadizadeh, & Joghataie, 2013; Klostermann, Braskie, Landau, O'Neil, & Jagust, 2012) 
accounting for reduced striatal volumes in MCI-S renders unlikely due to age- and gender-matched HCS. 
Rather, the result may indicate non-AD pathology in our MCI-S sample. Normal striatal volumes in MCI-
CB and MCI-CC in turn are most likely related to the early disease stages of each group. More precisely, 
striatal amyloid deposition and tangle formation have evidenced at late histopathological disease stages, 
and mainly after dementia onset (Beach et al., 2012; Braak & Braak, 1990, 1991a, 1991b; Thal et al., 
2002). Hence, the striatum in MCI-CB and MCI-CC may still be free of AD-typical pathology. 
Correspondingly, similar volumes of the striatum, putamen and caudate in MCI and future converters 
compared to HCS have been reported by others (Bossa et al., 2011; Leh et al., 2014; Roh et al., 2011). 
Previously reported reduced volumes of the striatum, putamen and caudate in AD patients (Bossa et al., 
2011; Cho et al., 2014; de Jong et al., 2014; Madsen et al., 2010; Roh et al., 2011) may in turn be related 
to later disease stages. 
As expected, however, shape analyses revealed no alterations in the striatum in MCI-S but pronounced 
displacements in MCI-CB and MCI-CC. The observed shape alterations were limited to the left striatum 
in MCI-CB, but displacements had further spread within the structure and to the right hemisphere in MCI-
CC. Aspects of the striatum showing most pronounced contractions and expansions such as the caudate 
head, body and tail as well as medial and lateral putamen have been linked to a wide range of cognitive 
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functions. More precisely, and as part of fronto-subcortical circuits, the anterior head and the body of the 
caudate nucleus, and the ventral lateral and medial putamen integrate major inputs from primary motor 
(Leh, Ptito, Chakravarty, & Strafella, 2007), dorsolateral and ventrolateral prefrontal (Leh et al., 2007), 
orbitofrontal, anterior cingulate (Haber, 2003) and middle temporal (de Jong et al., 2014) regions and are 
involved in cognitive processes such as attention, planning and memory (Cummings, 1995), all of them 
representing functions that are impaired early in AD (Klekociuk et al., 2014). Importantly, striatal shape 
alterations similar to the present ones have been associated with learning abilities in aMCI in another 
study from our group (Leh et al., 2014). 
Again, the study from Tang et al. (2014) represents the only study we are aware of having documented 
shape alterations in MCI-S and MCI-CB, without comparing their data to HCS data though. In agreement 
with other studies, however, they have demonstrated patterns of striatal contractions in MCI and AD 
patients (de Jong et al., 2014; Qiu et al., 2009; Tang et al., 2014) that were comparable to the patterns 
found in the current study. Interestingly, only a few studies have documented striatal expansions in 
general (de Jong et al., 2014; Tang et al., 2014), though these expansions were less pronounced than in 
the present study (visual inspection).  
It is beyond the aim of our study to draw direct inferences about the neuronal correlate of shape 
alterations. Given the pronounced connections with other disease-relevant structures, however, striatal 
and thalamic shape alterations may represent secondary downstream effects. A similar effect has been 
proposed by Stepan-Buksakowska et al. (2014). Specifically, volume reductions in the hippocampus and 
other early affected cortical regions may have caused subsequent morphometric changes in connected 
regions such as the thalamus and the striatum, without generating volume reductions yet. Although we 
cannot rule out the possibility of contractions representing atrophy-related alterations, the applied surface-
based shape analyses provides local, but not fully comprehensive information about the entire structure. 
Accordingly, and as it has been shown in the present study, structural shape alterations are not necessarily 
associated with corresponding volume changes. Hence, our results of shape differences in the absence of 
volume differences highlight the importance of considering shape changes along with established 
volume measures. 
 
Limitations 
Relatively small subject numbers may have limited statistical power and accounted for the fact that some 
effects did not quite achieve the level of significance. Low standard deviations (see Table 6 and 
Supplementary Table 1), however, support the reliability of the present results. Furthermore, a previous 
study from our group has reported similar results obtained by investigating morphometric changes in MCI 
and HCS samples of comparable sizes (Leh et al., 2014). We are therefore confident that the current 
results represent stable effects. Nevertheless, further studies are required to confirm our results in larger 
samples. 
Furthermore, the number of HCS that will convert to MCI and the number of MCI-S that will convert to 
AD in longer follow-up intervals is unknown, and we cannot rule out the possibility of future 
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conversions. This is particularly true for MCI-S subjects. Some authors have referred to this stage as 
potential early stage of AD (Bossa et al., 2011). Apart from slightly reduced striatal volumes, MCI-S have 
demonstrated no morphometric changes when compared to HCS in the present study, therefore reducing 
the likelihood of MCI-S representing an early disease stage. Additional markers of neurodegeneration 
such as CSF levels of phosphorylated Tau together with amyloid imaging may provide additional 
information in future longitudinal studies. The non-availability of these markers and of clinical measures 
providing information about disease severity in the present sample may raise the question of whether AD 
pathology is indeed at the basis of the observed subcortical shape alterations in the current study. The 
pattern of cortical thinning and hippocampal atrophy in MCI-CB and MCI-CC, together with absent 
morphometric alterations in MCI-S, however, are indeed highly supportive for AD pathology in MCI-CB 
and MCI-CC. 
The similar patterns of morphometric alterations in MCI-CB and MCI-CC are most likely related to the 
fact that both groups consisted of the same subjects, with MCI-CC data having been obtained at time of 
conversion. Hence, the time lag of approximately 20.8 months between MRI at baseline and at time of 
conversion might have been too short to reveal further progressed morphometric alterations. 
 
Conclusion 
The simultaneous presence of thalamic and striatal shape alterations, AD-typical cortical thinning and 
hippocampal atrophy in MCI-CB but not in MCI-S highlights the value of subcortical shape alterations as 
early marker for AD, and emphasizes the importance to consider regional morphological information of 
subcortical structures. It is now necessary to find ways allowing the implementation of advanced 
segmentation and analyses techniques in everyday clinical practice in the near future. 
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5.3.6 Supplementary data 
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6 General discussion 
 
The present work investigated whether within-domain IIV as well as thalamic and striatal shape 
alterations as cognitive and morphometric markers might support the identification of subjects at high risk 
for conversion to AD. Whereas this question could not be definitively answered with regard to the 
cognitive marker, the morphometric markers allowed the further characterization of future converters to 
AD. 
 
6.1 Within-domain intraindividual variability as early marker 
 
Results from study 1 investigating across- and within-domain IIV in HCS, MCI and AD have indeed 
provided support for within-domain IIV representing a potential early marker. Specifically, both across- 
and within-domain IIV were increased in AD versus HCS. However, across-domain IIV successfully 
discriminated between MCI and AD, whereas within-domain IIV successfully discriminated between 
MCI and HCS. Similar across-domain IIV in MCI and HCS as well as similar within-domain IIV in MCI 
and AD are most likely due to the varying levels of cognitive control functions elicited by the underlying 
tasks, the degree of impairment of cognitive control processes in the different groups (similar across-
domain IIV in HCS and MCI), and to very subtle characteristic of accuracy-based IIV in general, and 
within-domain IIV in particular (similar within-domain IIV in MCI and AD). Importantly, in agreement 
with the literature (Tractenberg & Pietrzak, 2011), similar difference scores (across- minus within-domain 
IIV) across groups indicated increasing accuracy-based IIV across diagnoses in general. Positive 
difference scores furthermore confirmed higher across- than within-domain IIV in all groups. This result 
indicates that impaired cognitive control functions affect performance in different cognitive control tests 
to a similar extent, and lead to rather low within-domain IIV. In contrast, inconsistent performance across 
tests representing cognitive domains most prone to show AD-related impairment, such as episodic 
memory (Albert et al., 2011) and short-term memory capacity (Schmitt et al., 2009), leads to higher 
across-domain IIV. Additionally, IIV was higher in APOE ε4 carriers than non-carriers. This, however, 
was only true for within- but not across-domain IIV, and only in HCS but not in MCI or AD. The present 
data, therefore, provide further support for the previously suggested relationship between cognitive 
control functions and APOE status (Duchek et al., 2009). It may, however, be that ε4-related changes in 
cognitive control functions and IIV appear in HCS but may not be evident by the MCI and AD stage due 
to increasing impairment in other cognitive domains. Thus, based on results from study 1, it was 
concluded that across-domain IIV tapping less cognitive control functions may detect incipient dementia 
and separate AD from MCI, whereas within-domain IIV tapping cognitive control functions more closely 
may constitute a potential marker for the detection of prodromal AD at the MCI stage.  
However, when longitudinal clinical information from MCI subjects was considered in study 2, within-
domain IIV as cognitive marker for the early detection was questionable. More precisely, within-domain 
IIV was similar in MCI-S and MCI-CB when compared to HCS, and the same was true when MCI were 
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combined across groups. As suggested by the literature (Ramratan et al., 2012; Vaughan et al., 2013) and 
by results from study 1, accuracy-based IIV in general might still be of low characteristic utility in MCI. 
Thus, the rather low sample size in study 2 might not have been sufficient to compensate for the low 
characterization of within-domain IIV in MCI-CB, leading to similar within-domain IIV in MCI-CB and 
HCS. Hence, it seems as if much larger sample sizes are required to observe a stable effect when 
investigating accuracy-based IIV in general, and within-domain IIV in particular. 
There is also the general question as to whether cognitive abilities allow the reliable identification of very 
early AD-relevant cognitive alterations, particularly when assessed on only one occasion. Impaired 
memory functions have gained attention and have been accepted as an early marker based on results from 
longitudinal studies clearly showing a decline up to a decade before the onset of AD (Amieva et al., 2014; 
Wilson et al., 2011), and being impaired already in HCS who later developed AD (Tabert et al., 2006; 
Venneri, Gorgoglione, et al., 2011; Wilson et al., 2012). Similar results have been shown for across-
domain IIV (i.e. Holtzer et al., 2008). Despite this highly valuable, retrospectively acquired information 
about longitudinal development of memory functions, the identification of AD-related memory alterations 
at such early stages and based on memory performance obtained from one single assessment represents 
an entirely different situation. Specifically, it is complicated by the lack of valid and reliable tests, 
appropriate normative data, or cut off scores allowing for the identification of subtle cognitive deficits. 
For example, high educational background (Amieva et al., 2014) or individual compensational strategies 
might leave cognitive functions in early MCI temporarily unimpaired. In contrast, low educational 
background (Amieva et al., 2014), individual weaknesses, or state-based fluctuations in cognition 
(Kliegel & Sliwinski, 2004) might affect cognitive performance, resulting in MCI-typical cognitive 
profiles in cognitively normal subject. Consequently, due to this deficit-oriented approach, cognitive 
impairment represents the last marker becoming abnormal, and the first clinical symptom in the 
biomarker model proposed by Jack et al. (2013). IIV has indeed been shown to provide information about 
cognitive functions above and beyond mean-level performance of standardized tests (Dixon et al., 2007; 
Hultsch et al., 2000), and the calculation of accuracy-based IIV does not require test-specific normative 
data or cut off scores. Thus, the use of IIV instead of mean-level performances in AD diagnosis might 
offer some advantage. Nevertheless, accuracy-based IIV relies on accuracy scores obtained from 
established cognitive tests, and thus, might suffer from similar limitations when assessed on one occasion. 
As has been shown for memory scores (e.g. Amieva et al., 2014) and across-domain IIV (e.g. Holtzer et 
al., 2008), measures of within-domain IIV across time might be necessary to overcome some of these 
limitations and provide more reliable and valid information about even subtle cognitive changes on an 
individual basis, irrespective of cognitive impairment. 
In summary, the early detection of future MCI or AD subjects solely based on test-associated cognitive 
markers might be restricted due to limitations that are inherent to the cognitive tests themselves. 
Importantly, however, cognitive measures might be of high relevance when combined with established 
biomarkers, as suggested by reports about improved prediction of conversion to AD when gray matter 
atrophy patterns (Da et al., 2014), hippocampal volumes and CSF markers (Eckerström et al., 2013) have 
been combined with cognitive markers.  
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6.2 Neuronal correlates of within-domain intraindividual variability 
 
There has only been one study investigating neuronal correlates of accuracy-based IIV so far, indicating a 
relationship between accuracy-based IIV and frontal gray but not frontal white matter volumes in elderly 
HCS (Lövdén et al., 2013). Thus, the authors have provided further support for the relevance of frontal 
brain regions for IIV, and for a possible relationship between accuracy-based IIV and gray matter 
volumes. However, IIV has been associated with cognitive control functions, and cognitive control 
functions have been suggested to be supported not only by frontal (Casey et al., 2007; Levy & Wagner, 
2011; Liston et al., 2006; Miller & Cohen, 2001; Weissman et al., 2006) but also by parietal cortices 
(Wilk et al., 2012). Considering increased within-domain IIV in MCI and AD (study 1), reduced 
cognitive control processes in AD (Rapp & Reischies, 2005; Schroeter et al., 2012) and AD-related 
cortical brain atrophy in IIV-relevant regions (e.g. Zhao et al., 2014), a relationship between within-
domain IIV and frontal as well as parietal gray matter volumes was thought to be highly likely. The lack 
of such a relationship in the present work, however, is most likely related to the absence of frontal or 
parietal atrophy not only in MCI-S but also in MCI-CB. Although some studies have indeed observed 
prefrontal (Han et al., 2012; Mosconi et al., 2013; Zhao et al., 2014) and parietal shrinking (Clerx et al., 
2013) in MCI or future converters subjects, others have failed to observe similar patterns (Burgmans et 
al., 2009; Zhang et al., 2013). These differences have most likely occurred due to different disease stages 
of MCI groups across studies. In particular, NFT in frontal and parietal regions have been identified at 
rather late histopathological disease stages (Braak & Braak, 1991b). Thus, MCI-CB subjects in the 
present work might have still been free of AD pathology. Apart from the non-existent prefrontal or 
parietal atrophy in MCI-CB, the low characterization of within-domain IIV might have further 
contributed to the lack of relationship between within-domain IIV and regional gray matter volumes. 
However, the lack of such a relationship even in MCI-S and HCS contrasts with results from Lövden et 
al. (2013) and raises the question of whether accuracy-based IIV is indeed associated with gray matter 
volumes in general. So far, most of the studies exploring neuronal correlates of IIV have investigated 
latency-based IIV, and have provided evidence for a relationship with frontal (Bunce et al., 2007; Jackson 
et al., 2012; Lövdén et al., 2013; Ullen et al., 2008) as well as parietal (Bellgrove et al., 2004; Jackson et 
al., 2012; MacDonald, Nyberg, et al., 2008; Ullen et al., 2008; Wilk et al., 2012) white matter alterations 
in elderly HCS. Likewise, similar relationships have also been found in MCI and AD (Anstey et al., 2007; 
Jackson et al., 2012). Interestingly, some of these studies have also investigated gray matter alterations 
but failed to identify comparable relationships (Lövdén et al., 2013; Moy et al., 2011; Ullen et al., 2008; 
Walhovd & Fjell, 2007). Providing further support for a link between white matter alterations and 
latency-based IIV, reaction time performance in general has previously been suggested to be associated 
with white matter integrity (Bender & Raz, 2012; Madden et al., 2004). Moreover, results from other 
studies have indicated a rather generalized relationship between mean reaction time performance and gray 
matter alterations, and between latency-based IIV and white matter alterations (Bunce et al., 2007; 
Walhovd & Fjell, 2007). Generally speaking, there is increasing evidence for the relevance of white 
matter alterations being at the basis of IIV. Thus, a similar relationship between frontal white matter 
alterations and accuracy-based IIV needs to be considered. Since accuracy- and latency-based IIV have 
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repeatedly been found to be associated (Hilborn et al., 2009; Hultsch et al., 2002), the idea of common 
neuronal correlates does not seem unreasonable, and has to be investigated in elderly HCS. Given 
increasing evidence for white matter pathology (Gold, Johnson, Powell, & Smith, 2012; Stokin et al., 
2005) and reduced white matter integrity in AD (Sun et al., 2014), such a relationship might also be at the 
basis of increased IIV in MCI and AD. However, the lack of a relationship between accuracy-based IIV 
and frontal white matter volumes in HCS in the study from Lövden et al. (2013) might indicate that white 
matter alterations beyond volume measurements might be necessary to shed further light on neuronal 
correlates of IIV in general. More precisely, since prefrontal cortex regions are involved in fronto-
subcortical circuits and act within distributed networks (Dosenbach et al., 2006), the investigation of a 
relationship between within-domain IIV and white matter connectivity in these networks in MCI and AD 
might help to provide further information about neuronal correlates of IIV. 
 
6.3 Thalamic and striatal shape alterations as early markers 
 
Results from study 3 indicated that subcortical shape alterations might be of high value for the early 
detection of AD. Specifically, as expected, thalamic and striatal shape alterations occurred in MCI-CB as 
well as MCI-CC, whereas they were absent in MCI-S when compared with HCS. Striatal and thalamic 
shape changes were paralleled by AD-like patterns of hippocampal total and subfield atrophy and 
mediotemporal cortical thinning in MCI-CB and MCI-CC but not in MCI-S. The results therefore support 
the presence of AD-related atrophy in MCI-CB and MCI-CC but not in MCI-S, and indicate an 
association between AD pathology and shape alterations. Thus, and by taking into account the presence 
of cognitive impairment and neurodegeneration, MCI-CB patients in the present work revealed an 
intermediate likelihood for conversion to AD following most current criteria for MCI due to AD (Albert 
et al., 2011). In contrast, MCI-S did not meet these criteria due to the lack of neurodegeneration. 
Although information about Aβ deposition in the brain was not available, the diagnosis of MCI due to AD 
renders unlikely. Supporting previous suggestions from others (Stepan-Buksakowska et al., 2014; Tang et 
al., 2014), the present results further emphasize the importance of considering local structural information 
from different structures in order to identify an AD-typical pattern of brain alterations in early AD.  
So far, many researchers have focused on measuring atrophy in medial temporal regions and comparing it 
between HCS, MCI and AD subjects. It has already been emphasized, however, that reduced gray matter 
volume sizes of single structures may not necessarily establish AD pathology (van de Pol et al., 2006). 
Accordingly, hippocampal atrophy has also been identified in forms of dementia other than AD (de Souza 
et al., 2013; La Joie et al., 2013; Lindberg et al., 2012; Tondelli et al., 2012). Hippocampal subfield 
analysis has indeed offered a more local approach (Wisse, Biessels, Heringa, et al., 2014), and 
hippocampal shape analysis has even evidenced additional predictive value over hippocampal volume for 
dementia in HCS (Achterberg et al., 2014). Thus, by taking into account the spreading pattern of AD 
pathology across the brain, the simultaneous investigation of shape and volume alterations of different 
structures represents a more appropriate approach to identify an AD-typical pattern of brain alterations. 
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Mixed results about thalamic and striatal atrophy in MCI and AD have been reported (see chapter 5 for an 
overview), most likely due to patient groups across studies representing different diseases stages. 
Nevertheless, subcortical structures such as the thalamus and the striatum in particular have been shown 
to be interesting and important in AD. Both structures consist of functionally different subfields which 
might be affected differently by AD pathology. A local approach is thus crucial. Both structures are 
furthermore connected with each other, and with regions that have shown early AD pathology such as the 
hippocampus (Zarei et al., 2010). Thus, both structures are involved in different neuronal circuits 
(Alexander et al., 1986; Bonelli & Cummings, 2007; Haber, 2003; Tekin & Cummings, 2002), and in 
different cognitive functions that are known to be impaired early in AD (Klekociuk et al., 2014). 
Moreover, anterior thalamic regions have revealed very early NFT pathology in AD (Braak & Braak, 
1991a, 1991b). The relevance of subcortical structure changes in AD has furthermore been indicated by 
recent studies from our own group reporting an association between subcortical amyloid load and brain 
tissue alterations in elderly HCS (Fluid-attenuated inversion recovery [FLAIR]) (Schreiner et al., 2014), 
and amyloid-related decreased network efficiency affecting the hippocampus and thalamus in elderly 
HCS (functional MRI) (Steininger et al., 2014).  
Only a few studies have investigated subcortical shape alterations in MCI and AD, though with promising 
results of shape alterations in the hippocampus, amygdala, thalamus, caudate and putamen in MCI and 
AD (Cho et al., 2014; de Jong et al., 2014; Stepan-Buksakowska et al., 2014; Tang et al., 2014). To the 
best of our knowledge at present, however, there has been only one study investigating subcortical shape 
alterations in future converters (Tang et al., 2014) without comparing their data to HCS though. Similar to 
results from studies investigating pooled MCI or AD (Cho et al., 2014; de Jong et al., 2014; Leh et al., 
2014; Qiu et al., 2009; Stepan-Buksakowska et al., 2014; Tang et al., 2014), thalamic and striatal shape 
alterations found in the present work have been identified in regions that are involved in AD-relevant 
cognitive functions (see chapter 5 for an overview). Accordingly, the present results as well as the 
literature support a pattern of striatal shape alterations in the caudate head, body and tail as well as in 
medial and lateral parts of the putamen, and thalamic alterations in anterior regions, the pulvinar, as well 
as medial dorsal aspects of the structure. However, shape alterations have also been identified in other 
parts of these structures (Cho et al., 2014; de Jong et al., 2014; Leh et al., 2014; Qiu et al., 2009; Stepan-
Buksakowska et al., 2014; Tang et al., 2014), indicating high variability across studies. Since thalamic 
and striatal shape alterations have additionally been documented in multiple sclerosis (Magon et al., 
2014), attention-deficit/hyperactivity disorder (Shaw, De Rossi, et al., 2014) and obsessive-compulsive 
disorder (Shaw, Sharp, et al., 2014), it is crucial to identify AD-relevant deformation patterns. Further 
studies are therefore necessary to investigate shape alterations in MCI in general, and in future converters 
in particular. 
Interestingly, as has been found by others (Cho et al., 2014; Tang et al., 2014), subcortical shape 
alterations in the present work occurred in the absence of volumetric alterations in the same structures. 
These results might indicate different neuronal correlates underlying shape and volumetric changes. 
However, there is as yet no clarity about the biological basis of contractions and expansions. 
Nevertheless, considering the surface-based approach applied in the present work, it must be recognized 
that shape analyses provide information about local deformations rather than fully comprehensive 
80 
 
information about the structure or its volume. Accordingly, in agreement with the present findings, 
structural shape changes are not necessarily accompanied by structural volume changes and vice versa. At 
the same time, we cannot altogether exclude the possibility of contractions representing atrophy (Cho et 
al., 2014), and the simultaneous presence of contractions and expansions might leave the overall volume 
unaffected. As discussed in the empirical part (chapter 5), however, striatal and thalamic shape changes in 
the present work might represent secondary downstream effects resulting from volume reductions in early 
affected cortical regions. Although accumulating proteins, axonal and dendritic loss, changes of synaptic 
structures or glial cells, or loss of cholinergic neurons may represent potential candidates, the neuronal 
basis of a potential secondary downstream effect, and of contractions and expansions remains unknown 
for the time being.  
 
6.4 Implications and directions for future research 
 
The present findings gave rise to new research questions. With regard to IIV, it will be fundamental to 
first investigate within-domain IIV longitudinally and by using much higher sample sizes to see whether 
stable effects of increased IIV present in future converters. Irrespective of its potential role in the early 
detection of AD, diffusion tensor imaging (DTI) analysis investigating the relationship between accuracy-
based IIV in general and white matter connectivity within fronto-subcortical networks in elderly HCS 
would be of high interest, and might provide further information about the neural underpinnings of 
accuracy-based IIV.  
With regard to subcortical shape alterations, further studies investigating thalamic and striatal shape 
alterations in future converters and AD are crucial to identify the typical deformation pattern that is 
associated with AD pathology.  
Both potential markers should be investigated with regard to their association with established biomarkers 
such as CSF tau or PET amyloid imaging. The presence of an association with high amyloid load in 
elderly HCS in particular would provide support for the value of subcortical shape alterations as 
preclinical marker for AD. PET amyloid imaging and future tau imaging might additionally help to 
provide more information about neuronal correlates of shape alterations in the AD disease process. 
Additionally, predictor analyses need to be performed to determine the established biomarker that deem 
most appropriate to improve the prediction of future conversion when combined with subcortical shape 
changes. Similar analyses need to be performed to find out whether within-domain IIV might contribute 
to the prediction of conversion when combined with more established biomarkers. 
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6.5 Conclusion 
 
The present work investigated the potential value of a newly developed cognitive measure and recently 
developed morphometric measures as early markers for AD.  
Within-domain IIV demonstrated questionable value as an early cognitive marker, and needs further 
exploration. In contrast, advanced imaging methods revealed that subcortical shape alterations in the 
thalamus and striatum, which were paralleled by AD-typical atrophy patterns in AD patients in the 
predementia stage, were promising for enhancing the early detection of AD. 
The present work also indicates that cognitive markers in general might be of limited value for the early 
detection of AD when compared with morphometric alterations. 
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